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ABSTRACT

SEVERELY STRESSED ASTROCYTES ADAPT TO INJURY AND STILL PROTECT
NEIGHBORING NEURONS

By
Amanda Marie Gleixner
December 2015

Dissertation supervised by Rehana K. Leak
Neurodegenerative disorders such as Parkinson’s and Alzheimer’s disease are projected
to affect 15.14 million people by the year 2050. All neurodegenerative diseases are characterized
by protein-misfolding stress, or proteotoxicity, in both neurons and glia. However, the impact of
proteotoxicity on glia is less well understood than in neurons. Astrocytes are an abundant type of
glia and play an essential role in brain homeostasis by supporting neuronal functions. Therefore,
one of the major goals of the present study was to identify ways to reduce the impact of
proteotoxicity in astrocytes. In Aim 1, we examined natural adaptations to proteotoxic stress in
astrocytes. Our studies demonstrate that the astrocytes surviving a severe proteotoxic insult are
resistant to subsequent challenges due to upregulation of the antioxidant biomolecule
glutathione. Prior to this body of work, only mild stressors were thought to elicit stress tolerance
and severe stress was thought to only weaken cells. In contrast with traditional views of reactive
iv

astrocytes, severely stressed astrocytes were still able to protect neighboring neurons from
proteotoxic injury in our model. In Aim 2, we examined the therapeutic potential of N-acetyl
cysteine, a glutathione precursor known to benefit patients with neurological disorders. We
discovered that N-acetyl cysteine protected astrocytes from proteotoxic stress independent of
glutathione. Instead, the protection afforded by N-acetyl cysteine was abolished by heat shock
protein inhibitors, suggesting a novel mechanism of action for N-acetyl cysteine in astrocytes. It
is important to promote heat shock protein activity in patients with neurodegenerative conditions
because loss of chaperone defenses may contribute to proteotoxicity in the elderly. In Aim 3, we
characterized the impact of aging on the expression of several heat shock proteins, many of
which are expressed in astrocytes. We discovered age-related changes in multiple heat shock
proteins in the substantia nigra, caudoputamen, and olfactory bulb, three regions known to
develop Lewy pathology in Parkinson’s disease. In conclusion, astrocytes can be protected
against protein-misfolding stress by upregulation of endogenous glutathione defenses or by Nacetyl cysteine treatment. Furthermore, some heat shock proteins are increased with aging,
perhaps as an endogenous defense against proteotoxic stress in older animals.
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Chapter 1 Introduction
1.1

Neurodegenerative diseases
Alzheimer’s and Parkinson’s disease are the most prevalent neurodegenerative disorders

and are becoming increasingly common as the United States’ population ages (Hebert, Weuve,
Scherr, & Evans, 2013; Kowal, Dall, Chakrabarti, Storm, & Jain, 2013). Patients with
Parkinson’s disease exhibit premotor (hyposmia, rapid eye movement disturbances), motor
(rigidity, resting tremor, dyskinesia), and nonmotor (depression, anxiety, psychosis) symptoms,
although the motor symptoms are the most easily recognized (Chaudhuri, Healy, & Schapira,
2006; Ponsen et al., 2004). Alzheimer’s patients exhibit memory loss, personality changes, and
cognitive impairments (Mega, Cummings, Fiorello, & Gornbein, 1996). The etiologies of
Parkinson’s and Alzheimer’s disease have not been established but are attributed to a
combination of genetic and environmental factors (Gatz et al., 2006; Warner & Schapira, 2003).
For example, residence in rural areas and chronic exposure to pesticides and herbicides are
known to increase the risk for developing Parkinson’s disease (McCormack et al., 2002).
Parkinson’s disease is more prevalent in men whereas women are at greater risk for developing
Alzheimer’s disease (Fratiglioni et al., 1997; Van Den Eeden et al., 2003). Both disorders place
an enormous physical and emotional toll on patients and their caregivers. It is estimated that
greater than 240 billion dollars are spent annually on caring for patients with these two
conditions (M. D. Hurd, Martorell, & Langa, 2013; Kowal, et al., 2013). Thus, it is imperative to
find treatments that will slow or halt the progression of these disorders.
1.1.1 Hallmark pathologies in Parkinson’s and Alzheimer’s disease
All neurodegenerative diseases are characterized by progressive cell loss in specific brain
regions over the course of years, if not decades. Vulnerable brain regions in these conditions are
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known to exhibit high levels of oxidative stress in postmortem analyses (Jenner, Dexter, Sian,
Schapira, & Marsden, 1992; Markesbery, 1997). For example, the hippocampus and cortex
exhibit increases in advanced glycation end productions, nitration, lipid peroxidation adduction,
and carbonyl-modified neurofilament proteins in Alzheimer’s patients (Adams, Klaidman,
Odunze, Shen, & Miller, 1991; Venkateshappa, Harish, Mahadevan, Srinivas Bharath, &
Shankar, 2012; Venkateshappa et al., 2012). In response to oxidative damage, numerous
compensatory changes in pro-survival molecules, such as glutathione, are also evident in these
disorders (Damier, Hirsch, Zhang, Agid, & Javoy-Agid, 1993; Mythri et al., 2011). Furthermore,
other antioxidant defense systems, such as heme oxygenase 1 (heat shock protein 32 (Hsp32) or
HO1) and superoxide dismutases are increased in neurodegenerative diseases (Jenner, 1992;
Mateo et al., 2010). The upregulation of endogenous antioxidant defenses may at least partly
explain the slow progression of neurodegeneration in these conditions. Thus, enhancing these
cellular defenses through pharmacological methods may further delay the progression of
neurodegenerative diseases.
Besides evidence of oxidative stress, another major hallmark of neurodegenerative
conditions is the stereotyped, progressive accumulation of protein aggregations in specific brain
regions (Braak, Ghebremedhin, Rub, Bratzke, & Del Tredici, 2004; Braak, Rub, Gai, & Del
Tredici, 2003; Braak, Rub, Schultz, & Del Tredici, 2006; Braak, Sastre, & Del Tredici, 2007).
For example, Parkinson’s patients exhibit alpha-synuclein+ Lewy bodies and Lewy neurites and
Alzheimer’s patients exhibit extracellular beta-amyloid plaques and intracellular neurofibrillary
tangles containing hyperphosphorylated tau (Hardy & Selkoe, 2002; Spillantini, Crowther, Jakes,
Hasegawa, & Goedert, 1998). The buildup of misfolded proteins in both conditions is thought to
inhibit the activity of the proteasomal and lysosomal protein degradation systems (Keller, Hanni,
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& Markesbery, 2000a; McNaught, Belizaire, Isacson, Jenner, & Olanow, 2003; McNaught &
Jenner, 2001). Thus, both Parkinson’s and Alzheimer’s disease are characterized by severe and
inexorable loss of protein homeostasis. This loss of protein homeostasis is also known as
proteotoxicity and is thought to propel and propagate oxidative stress (Alexandrova, Petrov,
Georgieva, Kirkova, & Kukan, 2008a; Morimoto, 2008). Conversely, reactive oxygen species
can oxidize proteins, disrupt their native conformations, and promote the formation of protein
aggregates (Davies, 1987; Floyd & Carney, 1992; Salvi, Carrupt, Tillement, & Testa, 2001). As
a result, normal protein functions may be impaired, leading to amplification of proteotoxicity and
further loss of homeostasis. In sum, restoration of redox and protein homeostasis may be
essential for the prevention of neurodegenerative diseases.
1.1.2 Astrocyte pathology in neurodegenerative conditions
Parkinson’s and Alzheimer’s pathologies are known to affect both neurons and glia,
although the neuronal changes have been investigated more thoroughly. Specifically, the impact
of neurodegeneration on astrocytes is less well understood. In Parkinson’s disease, astrocytes
contain alpha-synuclein+ protein aggregations in a topographic pattern that mimics the staged
appearance of neuronal inclusions across specific brain regions (Braak, et al., 2007; Guo,
Wharton, Moseley, & Shi, 2007; Wakabayashi, Hayashi, Yoshimoto, Kudo, & Takahashi, 2000).
As alpha-synuclein is a neuronal protein, these astrocytes are thought to engulf alpha-synuclein
from the extracellular space (Miyata et al., 2012). Astrocytes have also been observed to
accumulate beta-amyloid (1-42) in Alzheimer’s disease (Acunzo, Katsogiannou, & Rocchi,
2012). In both diseases, there is a robust increase in glial fibrillary acidic protein (GFAP), a
marker of astrocyte activation (Le Prince et al., 1993; Mythri, et al., 2011). Other
neurodegenerative diseases, such as Huntington’s disease and amyotrophic lateral sclerosis may
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also negatively impact astrocytes. Regions associated with neurodegeneration and glial
activation in Huntington’s disease exhibit an increase in small heat shock protein defenses
(Seidel et al., 2012). For example, astrocytes exhibit increased reactivity in the spinal cord of
amyotrophic lateral sclerosis patients compared to control subjects(Aronica, Catania, Geurts,
Yankaya, & Troost, 2001).
Astrocytes are known to be less susceptible than neurons to loss of protein homeostasis
and cell death than neurons in these conditions. For example, studies of primary neurons and
astrocytes reveal that neurons are more susceptible to proteasome inhibitors than astrocytes
(Dasuri et al., 2010). However, both neurons and astrocytes are known to increase heat shock
protein expression in response to proteotoxicity (Morimoto, 2008). These observations suggest
that both cell types can respond to and defend against proteotoxic stress. However, astrocytes
may mount better defenses than neurons because their role is to support damaged neurons and
build scar tissue in areas of severe injury. Alternatively, unlike most adult neurons, injured
astrocytes may continue to proliferate in order to maintain glial population numbers.
1.2 Ubiquitin proteasome system
1.2.1 Ubiquitin proteasome system structure and function
The ubiquitin proteasome system (UPS) is one of the major protein degradation systems
in eukaryotic cells. The UPS maintains protein homeostasis by degrading damaged proteins into
peptides that are then recycled into amino acids by peptidases. Both ubiquitin-conjugated and
oxidized proteins are degraded by the UPS (Lecker, Goldberg, & Mitch, 2006; Shringarpure,
Grune, Mehlhase, & Davies, 2003). Degradation of proteins through the UPS occurs within the
catalytic 26S proteasome particle and is dependent upon adenosine triphosphate (ATP)
(Ciechanover & Schwartz, 1994). The 26S proteasome consists of one 20S and two 19S protein
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complexes. The 19S subunits recognize proteins tagged for degradation with ubiquitin sidechains. The ubiquitin-conjugated proteins are then linearized to facilitate their entrance into the
barrel-like structure of the 20S subunit. Efficient enzymatic degradation of proteins into peptides
occurs in the 20S subunit by chymotrypsin-, trypsin-, and caspase-like enzymatic activities (D.
H. Lee & Goldberg, 1998).
Cytosolic proteins destined for degradation by the UPS are tagged with ubiquitin through
three enzymatic steps (Pickart, 2001). Ubiquitin activating enzymes are designated as E1
enzymes and hydrolyze ATP and adenylate the ubiquitin molecule. After adenylation of
ubiquitin by E1, ubiquitin conjugating enzymes, designated as E2 enzymes, transfer ubiquitin to
the cysteine residues of the misfolded protein. Subsequently, ubiquitin ligating enzymes
designated as E3 enzymes catalyze the transfer of ubiquitin from E2 to the target protein. The
target protein must be labeled with at least four ubiquitin molecules prior to its recognition by the
proteasome (Deveraux, Ustrell, Pickart, & Rechsteiner, 1994). Finally, proteins destined for
proteasomal degradation are tagged by ubiquitin molecules that are linked through lysine 48 of
the adjacent ubiquitin, also known as K48-linked ubiquitin (Jacobson et al., 2009). Because of
the essential nature of the UPS, inhibitors of this protein clearance system elicit protein
aggregations and cell death.
1.2.2 Impact of Parkinson’s and Alzheimer’s disease on the ubiquitin proteasome system
Impairment of the UPS has been observed in postmortem tissue from Parkinson’s disease
and Alzheimer’s disease patients. For example, chymotrypsin, trypsin, and caspase enzymatic
activity are decreased in the substantia nigra of Parkinson’s disease patients relative to age
matched controls (Cook & Petrucelli, 2009; McNaught & Jenner, 2001). Similarly, chymotrypsin
activity of the proteasome was decreased (relative to age-matched controls) in the hippocampus
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of brains obtained from Alzheimer’s disease patients (Keller, Hanni, et al., 2000a). Furthermore,
the substantia nigra of Parkinson’s disease patients harbors fewer proteasomal subunits than in
control patients (Cook & Petrucelli, 2009). Alpha-synuclein, a major component of Lewy bodies
and Lewy neurites, is known to inhibit the activity of the UPS and to propagate proteotoxicity
(Lindersson et al., 2004). Under some conditions, impaired UPS activity may cause the cells to
shift towards autophagic degradation of proteins (Cecarini et al., 2014). However, in
neurodegenerative disorders, autophagic protein clearance is also compromised, leading to
severe loss of protein homeostasis (Anglade et al., 1997; Cuervo, Stefanis, Fredenburg,
Lansbury, & Sulzer, 2004; Nixon et al., 2005).
1.2.3 Modeling impairments in the ubiquitin proteasome system
Pharmacological inhibitors targeting the UPS elicit proteasome impairment and
proteotoxicity and are used to model neurodegenerative diseases in vitro and in vivo (Rideout,
Larsen, Sulzer, & Stefanis, 2001; Rideout & Stefanis, 2002; Sawada et al., 2004; F. Sun et al.,
2006). MG132 (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal) is a peptide aldehyde that
reversibly inhibits the chymotrypsin-like activity of the 26S proteasome (Alexandrova, Petrov,
Georgieva, Kirkova, & Kukan, 2008b; Braun et al., 2005; Kisselev & Goldberg, 2001). Although
MG132 has also been shown to inhibit proteases such as cathepsin A, cathepsin B, and calpain
(Ostrowska, Wojcik, Omura, & Worowski, 1997; Rivett & Gardner, 2000; Shirley et al., 2005),
all of these effects converge to elicit loss of protein homeostasis or proteotoxicity. Thus,
experiments using MG132 are thought to model proteotoxic stress and not merely proteasome
inhibition. Additional proteasome inhibitors with different mechanisms of action include
lactacystin. Lactacystin is a cyclic amide that covalently binds β2 of the 20S subunit of the
proteasome and irreversibly inhibits UPS protein clearance (D. H. Lee & Goldberg, 1998). As
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with all inhibitors, the effects of lactacystin are not limited to the proteasome because lactacystin
also inhibits cathepsin B (D. H. Lee & Goldberg, 1998).
1.3 Heat shock proteins
1.3.1 Heat shock protein biology and defense against proteotoxicity
In response to proteotoxicity, cells are known to upregulate pro-survival molecules that
reduce loss of protein homeostasis and combat cell death. Heat shock proteins are molecular
chaperones that refold misfolded proteins, aid in protein degradation by the UPS and lysosome,
and activate the unfolded protein response in the endoplasmic reticulum (Walter & Ron, 2011).
Heat shock proteins also inhibit caspase-mediated apoptosis. Heat shock proteins can be
constitutively expressed (e.g. heat shock cognate 70 (Hsc70)) or stress induced (e.g. heat shock
protein 70 (Hsp70) and heat shock protein 27 (Hsp27)). These proteins are typically grouped
into high molecular weight (e.g. Hsp70 and heat shock protein 90 (Hsp90)) and small heat
shock proteins (e.g. Hsp27). Typically, the high molecular weight heat shock proteins are ATPdependent whereas the small heat shock proteins are ATP-independent (Lanneau, Wettstein,
Bonniaud, & Garrido, 2010).
Hsp70 is the best-studied member of the heat shock protein family and is comprised of
three interdependent domains: N-terminal ATPase domain, peptide binding domain, and a
helical lid domain (Lanneau, et al., 2010). The coordinated functions of these protein domains
determine Hsp70 folding activity. A number of co-chaperones drive Hsp70-mediated protein
degradation or protein refolding. For example, Hsp70-mediated protein degradation is
facilitated by binding to the co-chaperones BAG1 and CHIP. BAG1 binds to the ATPase
domain while CHIP, a ubiquitin ligase, binds to the substrate-binding domain. Alternatively, the
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co-chaperone heat shock protein 40 (Hsp40) binds to the ATPase domain of Hsp70 to stimulate
the refolding of proteins bound to the Hsp70-misfolded protein complex.
In addition to refolding misfolded proteins and promoting intracellular protein
degradation, Hsp70 attenuates oxidative stress and may be released by exosomes to work in the
extracellular space (Taylor, Robinson, Gifondorwa, Tytell, & Milligan, 2007). For example,
astrocytes are known to release Hsp70, which may offer protection against the proteotoxicity in
neighboring cells (Taylor, et al., 2007). Hsp70 may also attenuate cellular damage by
upregulating glutathione defenses. For example, Guo and colleagues have shown that overexpression of Hsp70 increases glutathione reductase and glutathione peroxidase activity after
oxygen glucose deprivation (Guo, et al., 2007). Hsp70, unlike Hsc70, is susceptible to oxidation
at cysteine residues (Miyata, et al., 2012). These findings suggest that Hsp70 may be sensitive
to oxidative stress and regulate redox cycling and glutathione defenses in additional to its
traditional chaperone functions. Hsp70 is also known to inhibit caspase-mediated apoptosis
(Beere et al., 2000; Ravagnan et al., 2001). Hsp27 (or the murine form Hsp25) is able to
attenuate apoptosis in addition to its role in enhancing catalytic activity of the proteasome
(Acunzo, et al., 2012; Lanneau, et al., 2010).
As mentioned above, disruption of protein homeostasis usually occurs in association with
oxidative stress. Some heat shock proteins are known to decrease oxidative stress. HO1 (also
known as Hsp32) is involved in antioxidant defense and breaks down toxic heme into the
reactive oxygen species scavenger biliverdin and the prosurvival molecule carbon monoxide
(Schipper, 2011). Many studies have shown that HO1 is increased in astrocytes in
neurodegenerative conditions, possibly as a compensatory response (Schipper, 2011; Schipper,
Liberman, & Stopa, 1998).
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Proteotoxicity is often measured in the cytoplasm. However, proteotoxicity is also
observed in the endoplasmic reticulum and can be reversed through the unfolded protein
response. Glucose-regulated protein 78 kDa (GRP78) is a member of the same chaperone
family as Hsp70 and mediates the unfolded protein response (Walter & Ron, 2011). Heat shock
protein 60 (Hsp60) is typically associated with mitochondrial proteotoxicity and is responsible
for refolding misfolded proteins (Saibil, 2013), (Clare & Saibil, 2013).
1.3.2 Inhibition of heat shock protein activity
In order to study the role of heat shock proteins, several small molecules inhibitors have
been developed to decrease heat shock protein activity. Inhibition of Hsp70 activity can occur
via blockade of the ATPase and/or substrate binding domains. There are three major classes of
Hsp70 inhibitors. VER155008, an adenosine-derived inhibitor, binds to the active site of Hsp70
and Hsc70 to inhibit ATPase activity (Chatterjee et al., 2013; Massey et al., 2010; Schlecht et al.,
2013). MAL3-101 is an allosteric Hsp70 inhibitor and interferes with the interaction of Hsp40
and the ATPase domain of Hsp70 (Adam et al., 2014; Fewell et al., 2004; Huryn et al., 2011). 2phenylethynsulfonimide (PES or pifithrin-µ) is a small molecule inhibitor and binds to the
substrate binding domain of Hsp70 to attenuate chaperone activity (Granato et al., 2013; Kondoh
& Osada, 2013; Leu, Pimkina, Frank, Murphy, & George, 2009; Leu, Pimkina, Pandey, Murphy,
& George, 2011). HO1 activity can be inhibited by tin protoporphyrin IX (SnPPx), which
competes with heme for the active site of the enzyme (Drummond & Kappas, 1981; Yoshinaga,
Sassa, & Kappas, 1982).
1.3.3 Heat shock protein changes in Parkinson’s disease
As neurodegenerative diseases are characterized by the accumulation of misfolded
proteins, heat shock proteins are often upregulated in these conditions and bound to protein
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aggregations. For example, Hsp70 is found in Lewy bodies and Lewy neurites in Parkinson’s
patients (McNaught, Shashidharan, Perl, Jenner, & Olanow, 2002). Increases in Hsp27 and HO1
have been observed in astrocytes in Parkinson’s disease (Renkawek, Stege, & Bosman, 1999;
Schipper et al., 2006). Although heat shock protein levels are increased in neurodegenerative
conditions, their activity may not be sufficient to fully attenuate or reverse proteotoxicity. On the
other hand, it seems likely that they are partly responsible for the slow progression of these
disorders given their established roles in protein folding and degradation.
1.3.4

Heat shock protein changes with aging
Aging is thought to be the major risk factor for neurodegenerative diseases, perhaps

because of accrual of oxidative and proteotoxic damage. Age-related increases in cellular stress
may be attributed to a decline in proteasome and autophagic systems and an increase in
mitochondrial dysfunction (Keller, Gee, & Ding, 2002; Keller, Huang, & Markesbery, 2000; H.
C. Lee & Wei, 2012; Martinez-Vicente, Sovak, & Cuervo, 2005). In normal aging, protein
aggregations often appear in the olfactory bulb (Attems, Lintner, & Jellinger, 2005). Aging has
also been associated with degeneration of dopaminergic neurons in the substantia nigra and a
decline in striatal dopamine levels, although other studies have failed to observe age-related
decreases in dopamine neurons (Gibb & Lees, 1991; Kish, Shannak, Rajput, Deck, &
Hornykiewicz, 1992; McCormack et al., 2004). Furthermore, striatal volume is known to
decrease with age (Raz et al., 2003).
There are conflicting reports of changes in heat shock proteins with aging. Calabrese and
colleagues observed an age-related increase in Hsp70 in the cortex, striatum, and hippocampus,
whereas Arumugam and colleagues observed an age-related decrease in Hsp70 in the cortex and
striatum (Arumugam et al., 2010; V. Calabrese et al., 2004). However, many studies are in
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agreement that Hsp25/Hsp27 expression is increased with natural aging (Dickey et al., 2009;
Gupte et al., 2010; Schultz et al., 2001). Advancing age is associated with a decrease in GRP78
in the cortex, striatum, and hippocampus but an increase in the substantia nigra (Alladi et al.,
2010; Arumugam, et al., 2010; Hussain & Ramaiah, 2007; Paz Gavilan et al., 2006). Hsc70 is
reported to increase with aging in the pons, medulla, striatum, thalamus, and substantia nigra (V.
Calabrese, et al., 2004; Unno et al., 2000). Declines in heat shock proteins may contribute to
disruption of protein homeostasis associated with aging while increases may help mitigate agerelated proteotoxic stress.
1.4 Astrocyte biology
1.4.1 Neurosupportive role
Astrocytes, once thought to be merely “brain glue,” are essential for many neuronal and
extraneuronal functions (Allen & Barres, 2009). For example, astrocytes are the primary source
of glutathione in the brain and can robustly upregulate heat shock protein defenses (Dringen,
2000; Dringen, Gutterer, & Hirrlinger, 2000; Schipper, et al., 2006; Schipper, et al., 1998). As
mentioned above, astrocytes are also known to release Hsp70 into the extracellular space via
exosomes (Taylor, et al., 2007). Some authors have argued that astrocytes play a toxic role
(Gouix et al., 2014; Jana & Pahan, 2010). Although this may be the case in some disease states,
it seems likely that astrocytes are more often protective given their overwhelmingly supportive
nature. In other words, if astrocytes were absent from the diseased brain, one would expect even
greater neuronal injury.
1.4.2 Primary source of brain glutathione
Neurons and glia are both equipped to synthesize glutathione. Nevertheless, astrocytes
are the primary source of glutathione in the central nervous system (Dringen, 2000). Astrocytes
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can promote neuronal glutathione synthesis by releasing glutathione and glutathione precursors
into the extracellular space. Glutathione precursors, such as glutamate and cysteine, are then
taken up by neurons for de novo glutathione synthesis (Dringen, et al., 2000; Dringen, Pfeiffer, &
Hamprecht, 1999).
1.5 Glutathione
Glutathione is the most abundant antioxidant found throughout the body and can exist in
millimolar concentrations (Aquilano, Baldelli, & Ciriolo, 2014; Meister & Anderson, 1983).
Glutathione plays an important role in the metabolism of xenobiotics via glutathione Stransferase, enzymatic elimination of peroxides, and reduction of free radicals through the
cysteine thiol.
1.5.1 Synthesis and regulation
Glutathione is a tripeptide molecule comprised of glutamate, cysteine, and glycine.
Glutathione production relies on the availability of synthetic enzymes (glutamate cysteine ligase
and glutathione synthetase) and glutathione substrates. The transcription factor nuclear factor
(erythroid-derived 2)-like 2 (Nrf2) regulates glutamate cysteine ligase (GCL) and glutathione
synthetase (GS) transcription. Under basal conditions (no oxidative stress), Nrf2 is bound to
Kelch-like ECH-associated protein (Keap1). Reactive oxygen species can react with the
cysteines on Keap1 to elicit its dissociation from Nrf2 (Fourquet, Guerois, Biard, & Toledano,
2010; D. D. Zhang & Hannink, 2003). Upon dissociation from Keap1, Nrf2 translocates to the
nucleus and induces GCL and GS transcription, among other genes. If glutathione substrate and
synthetic enzyme levels are sufficient, the first step of glutathione synthesis can proceed and
GCL ligates glutamate and cysteine. GCL activity is regulated by modifier (GCLM) and catalytic
(GCLC) subunits. GCLM has been shown to promote the enzymatic efficiency of GCLC (S. C.
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Lu, 2009). In the final synthetic step, glycine is incorporated into the glutamate-cysteine
molecule by GS (S. C. Lu, 2013).
Cysteine availability is a rate-limiting factor in glutathione synthesis. The membrane
transporter system xc- is responsible for importing cystine or cysteine while exporting glutamate.
Once imported, cystine can be converted to cysteine by cystine reductase. Astrocytes are known
to express system xc- and thereby obtain the cysteine necessary for glutathione synthesis. The
prodrug N-acetyl L-cysteine (NAC) can provide the L-cysteine for the glutathione synthetic
pathway (Zhou et al., 2015). NAC can also activate system xc- and thereby promote glutathione
synthesis (Baker et al., 2003).
The amino acid cysteine can exist in two isomeric forms: L-cysteine and D-cysteine. Lcysteine is the highly abundant form of cysteine and can be incorporated into glutathione. Dcysteine cannot be used in glutathione synthesis and is not readily found in cells. However, both
L- & D-cysteine can decrease reactive oxygen species through their sulfhydryl group. The
sulfhydryl group donates a hydrogen molecule and neutralizes free radicals. D-amino acid
oxidase and D-aspartate oxidase interconvert L- & D-amino acids (Friedman & Levin, 2012;
Sacchi et al., 2008). D-amino acid oxidase is thought to convert D-cysteine to L-cysteine to
increase glutathione synthesis. Thus, D-cysteine-mediated protection in the absence of D-amino
acid oxidase activity would be suggestive of thiol-mediated effects.
Glutathione synthesis is a tightly regulated process. Upon exposure to oxidative stress,
there is rapid activation of Nrf2, as outlined above, and this promotes transcription and
translation of the enzymes that synthesize glutathione (Taguchi, Motohashi, & Yamamoto,
2011). Conversely, cells also negatively regulate glutathione synthesis in the presence of excess
glutathione. For example, high levels of glutathione inhibit further glutathione synthesis by
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blocking GCL activity (Franklin et al., 2009). This process of glutathione synthesis blockade can
be replicated with buthionine sulfoximine (BSO), a reversible, competitive inhibitor of GCL
(Griffith, 1982; Griffith & Meister, 1979). Methionine sulfoximine and etanidazole also inhibit
glutathione synthesis but are thought to be less specific than BSO (Griffith, 1982).
Aside from synthesizing glutathione, astrocytes are known to tightly regulate the oxidized
and reduced form of glutathione. Glutathione becomes oxidized when glutathione peroxidase
converts hydrogen peroxide into water and oxygen. This enables astrocytes to prevent oxidative
damage from the production and accumulation of hydrogen peroxide. The oxidized form of
glutathione is readily converted back to the reduced form by glutathione reductase. Glutathione
is primarily found in the reduced form, permitting it to exert antioxidant effects (Owen &
Butterfield, 2010).
1.5.2 Changes in glutathione defenses associated with neurodegenerative diseases
Table 1 highlights some of the changes in glutathione and glutathione-related proteins in
various neurodegenerative diseases (Adams, et al., 1991; Damier, et al., 1993; Maher, 2005;
Mythri, et al., 2011; Pearce, Owen, Daniel, Jenner, & Marsden, 1997; Sian et al., 1994). A net
decrease in glutathione relative to age-matched control patients has been observed in brain
regions highly susceptible to Parkinson’s disease, such as the substantia nigra (Pearce, et al.,
1997; Sian, et al., 1994; Sofic, Lange, Jellinger, & Riederer, 1992). An early decrease in reduced
glutathione in neurons of the substantia nigra may exacerbate subsequent cell death in this region
in Parkinson’s disease. Despite the net decrease in glutathione in degenerating brain regions, a 35 fold increase in total glutathione has been observed in less susceptible brain regions in
Parkinson’s patients such as the frontal cortex, caudate nucleus, and putamen (Mythri, et al.,
2011). Furthermore, glutathione peroxidase+ astrocytes are significantly increased in the
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substantia nigra in Parkinson’s patients relative to age-matched control subjects (Damier, et al.,
1993). Therefore, astrocytes seem to engage in some compensatory responses in
neurodegenerative conditions. However, the compensatory increase in glutathione defenses in
astrocytes is not sufficient to halt disease progression. Future explorations of therapies that
enhance astrocytic glutathione defense at earlier stages of neurodegeneration or lead to even
greater increases in glutathione defenses are highly warranted.
The family of cytosolic glutathione S-transferase enzymes is subdivided into classes
based upon N-terminal domain amino acid sequence (Mazzetti, Fiorile, Primavera, & Lo Bello,
2015). Two of the cytosolic glutathione S-transferase classes are π and μ. Glutathione Stransferase μ is primarily found in astrocytes under physiological conditions whereas glutathione
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S-transferase π, normally found in oligodendrocytes, is found in reactive astrocytes (Arumugam,
et al., 2010; V. Calabrese, et al., 2004; Unno, et al., 2000). Glutathione S-transferase is primarily
recognized for its conjugation of glutathione to xenobiotics, thereby eliciting cellular protection
(Mazzetti, et al., 2015). Glutathione S-transferase π and μ can also be protective through
regulation of the stress kinase pathways (Adler et al., 1999; Cho et al., 2001). Both π and μ
classes of glutathione S-transferase may be important for decreasing the oxidative stress
associated with Parkinson’s and Alzheimer’s disease. Polymorphisms in glutathione Stransferase π have been associated with an increased risk for developing Parkinson’s disease in
individuals who smoke (Hussain & Ramaiah, 2007). Furthermore, loss of glutathione Stransferase π activity is associated with increased susceptibility of dopaminergic neurons in a
mouse model of Parkinson’s disease (Paz Gavilan, et al., 2006). Alterations in the glutathione Stransferase π 1 gene sequence are linked to earlier cognitive decline in Alzheimer’s disease
patients (Alladi, et al., 2010). The glutathione S-transferase μ 1 null genotype is associated with
an earlier onset of Parkinson’s disease (V. Calabrese, et al., 2004). In addition, a significant
association between glutathione S-transferase μ 1 null polymorphisms and Parkinson’s disease
has been observed in Chilean populations with a strong American genetic component
(Arumugam, et al., 2010). Consistent with these observations, a combination of the glutathione
S-transferase μ 1 null genotype and prior exposure to pesticides is more frequently observed in
Parkinson’s disease patients than in control subjects (McCormack, et al., 2004). Furthermore,
Piacentini and colleagues found a positive association between glutathione S-transferase μ 1 null
genotypes and late onset Alzheimer’s disease (Raz, et al., 2003). Thus, glutathione S-transferase
may be a reasonable target to slow or halt neurodegenerative disease progression.
1.5.3 Therapeutic approaches to increasing glutathione
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Several clinical trials have explored increasing glutathione levels as a therapeutic
approach to blunting the progression of neurodegenerative diseases. For example, clinical trials
have shown that NAC increases blood and brain glutathione levels in Parkinson’s patients
(Holmay et al., 2013). Adair and colleagues showed that NAC improved some aspects of
cognitive function in Alzheimer’s disease patients (Adair, Knoefel, & Morgan, 2001). Similarly,
NAC dramatically improved the resolution of neurological symptoms in soldiers that
experienced traumatic brain injury in combat settings (M. E. Hoffer, Balaban, Slade, Tsao, &
Hoffer, 2013). NAC has also been shown to improve some of the clinical symptoms of
schizophrenia and bipolar disorder (Attems, et al., 2005; Gibb & Lees, 1991). The beneficial
effects of NAC in neurodegenerative and psychiatric diseases may result from enhanced
glutathione synthesis and decreases in oxidative damage.
1.6 N-acetyl L-cysteine
1.6.1 Up-regulation of antioxidant response element and heat shock factor 1
Because NAC contains a sulfhydryl group and participates in thiol exchange reactions, it
may interact with the cysteine residues in Keap1 and heat shock factor 1 (HSF1). HSF1
activation results in its translocation to the nucleus and Hsp70 gene induction. This hypothesis is
consistent with previous work showing that NAC upregulates Hsp70 in neuroblastoma cells
under conditions of proteotoxic stress (Jiang et al., 2013). As mentioned above, Keap1
modification via thiol exchange reactions enhances Nrf2 activity and subsequent transcription of
genes such as those that encode for Hsp70 and those under the control of the antioxidant
response element (Hu et al., 2006; Kwak et al., 2003). Thus, NAC may have protective effects
through direct antioxidant activity, as a glutathione prodrug, and through thiol exchanges with
Keap1 and HSF1 that lead to the induction of pro-survival genes.

17

1.7 Adaptations to cellular stress
1.7.1 Preconditioning
Cellular adaptations to stressors are often studied in the context of low level, subtoxic
stress. Exposure to subtoxic stress often promotes endogenous defenses that improve survival
following subsequent challenges. This phenomenon is known as preconditioning or tolerance (E.
J. Calabrese et al., 2007). Self-protection in response to cellular stress depends both on the
concentration and duration of the injury (Leak, 2014). Exposure to subtoxic insults may elicit the
upregulation of endogenous defensive molecules such as Nrf2 and HO1 (Bell et al., 2011;
Garnier et al., 2001; Xu et al., 2014).
Many studies have established that astrocytes can be preconditioned by subtoxic stress.
For example, hypoxic preconditioning of astrocytes enhances their neuroprotective properties
(Sen et al., 2011). Astrocyte-mediated neuroprotection may be facilitated by an increase in
glutamate uptake following ischemic insults. Astrocytes can then convert glutamate to glutamine
and decrease excitotoxicity (Maragakis & Rothstein, 2006). Furthermore, transfer of astrocyteconditioned media from preconditioned astrocytes to neurons decreases neuron apoptosis (Saibil,
2013). In sum, astrocytes exposed to low level cellular stressors are protected against subsequent
insults and maintain their ability to support neuronal functions.
Although it is well established that astrocytes and other cells can adapt to low level stress,
it is not known if cells can adapt to severe proteotoxic stress such that they are protected against
subsequent challenges. Instead, high levels of cellular stressors are generally thought to elicit
additive or synergistic toxicity, as predicted by the dual hit hypothesis of neurodegeneration
(Boger, Granholm, McGinty, & Middaugh, 2010; Sulzer, 2007; Unnithan, Choi, Titler, Posimo,
& Leak, 2012; Zhu, Lee, Perry, & Smith, 2007). As astrocytes are known to be a highly resilient
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cell type, they seem well suited to test the hypothesis that some cells can adapt to both subtoxic
and toxic stress, with the latter being defined as stress that is lethal to some fraction of the
cellular population (Walter & Ron, 2011). The slow and progressive nature of neurodegenerative
disorders is consistent with the notion that some severely stressed cells are able to resist
subsequent challenges better than stress-naïve cells. This process might enrich the affected brain
region in cells that become increasingly difficult to kill, thereby delaying the progression of the
disease, perhaps for decades. Whether severely stressed astrocytes mitigate or exacerbate
neuronal injury is also not well understood. However, this is an important question to answer
because if astrocytes can adapt to severe stress conditions, they might be able to support
neighboring neurons more effectively.
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Chapter 2 Materials and Methods
Cortical astrocyte cultures Use of animal tissue was conducted in accordance with the NIH
Guide for the Care and Use of Laboratory Animals following Institutional Animal Care and Use
Committee approval. Primary cortical astrocytes were harvested as previously published (Titler,
Posimo, & Leak, 2013). Briefly, the cerebral cortex of postnatal day 1-2 Sprague-Dawley rats
(Charles River, Wilmington, MA) was dissected under sterile conditions and incubated in 0.25%
Trypsin-EDTA (Cat. no. 25200, Gibco Life Technologies, Grand Island, NY) at 37 °C for 7 min
before washes and dissociation with a 5 mL serological pipet. For dual hit studies (part I), the
cell culture medium was comprised of Basal Medium Eagle (Cat. No. B1522, Sigma-Aldrich)
supplemented with bovine calf serum (Cat. No. 2151, HyClone Thermo Scientific), 35 mM
glucose (Cat. No. G8769, Sigma-Aldrich, St. Louis, MO), 1 mM L-glutamine (Cat. No. 25030081, Gibco, Life Technologies), 50 Units/mL penicillin, and 50 µg/mL streptomycin (Cat. No.
15140-122, Gibco, Life Technologies). For dual hit studies (part II) and the N-acetyl cysteine
studies, the cell culture medium was composed of Dulbecco’s modified Eagle medium (DMEM,
Cat. no. 12100061, Gibco Life Technologies) with 10% Fetal Clone III (Cat. no. SH30109.03,
Thermo Scientific Hyclone, Logan UT), penicillin and streptomycin (50 U/mL and 50 µg/mL,
respectively; Cat. no. 15070, Gibco Life Technologies). Dissociated cells were counted under
Trypan blue exclusion and 24 x 106 cells were plated on T175 flasks coated with poly-D-lysine
(10 µg/mL; Cat. no. P0899, Sigma-Aldrich). Flasks were incubated at 37°C and 5% CO2 for 7-10
days and non-astrocytic cells were removed by orbital shaking at 260 revolutions per minute
overnight at 37°C. The media was removed from these flasks and replaced with fresh cell culture
medium as described above. Astrocyte cultures were then incubated for an additional 2-3 days
before trypsinization and plating for experimental procedures, at which point they might be
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considered secondary astrocyte cultures. Astrocyte cultures were maintained and used for
experiments for up to one month.
For Part I of the dual-hit studies, astrocytes were plated at 40,000 cells/well in 96-well
plates for viability experiments. For Part II of the dual hit studies and the investigation of Nacetyl cysteine (NAC), cells were plated at a density of 20,000 cells/well in 96-well plates for
viability experiments and 6.8 × 105 cells/well in 6-well plates for Western blotting (Costar,
Corning Incorporated, Corning, NY). Under both conditions, the astrocytes formed a confluent
monolayer at the time of experimentation.
Primary neuron cultures Neocortical tissue was harvested from postnatal day 1-2 Sprague
Dawley pups as previously published (Posimo, Titler, Choi, Unnithan, & Leak, 2013). Briefly,
primary neuronal cultures were prepared by first incubating neocortical tissue in 10 Units/mL
papain (Cat. No. P3125, Sigma-Aldrich) for 30 min at 37 °C. The tissue was then transferred to
10% type II-O trypsin inhibitor (Cat. No. T9253, Sigma-Aldrich) at room temperature followed
by mechanical dissociation in Basal Medium Eagle (Cat. No. B1522, Sigma-Aldrich)
supplemented with 10% bovine calf serum (BME/BCS, Cat. No. 2151, HyClone Thermo
Scientific), 35 mM glucose (Cat. No. G8769, Sigma-Aldrich), 1 mM L-glutamine (Cat. No.
25030-081, Gibco, Life Technologies), 50 Units/mL penicillin, and 50 µg/mL streptomycin (Cat.
No. 15140-122, Gibco, Life Technologies). Cells were then plated at a density of 80,000
cells/well in Opti-MEM (Cat. No. 51985-034, Gibco, Life Technologies) with 20 mM glucose on
a 96 well plate coated with poly-D-lysine (1 µg/mL) and laminin (Cat. No. 354232, 1.88 µg/mL,
Corning Incorporated). After a 2 hour incubation at 37 °C, Opti-MEM was replaced with
Neurobasal A medium (Cat. No. 10888-022, Gibco Life Technologies) supplemented with 2%
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v/v B27 (Cat. No. 17504-044, Invitrogen Life Technologies) and L-glutamine (1:50, Cat. No.
25030-081, Gibco Life Technologies). Neuronal cells were treated two days after plating.
Neuron-astrocyte co-cultures Purified cortical astrocytes (as described above) were plated and
treated with the 1st MG132 hit or vehicle in astrocyte cell culture medium. Primary neocortical
neurons were plated on top of cortical astrocytes in Neurobasal-A Medium. Two days after
plating the neurons, the 2nd MG132 hit was delivered. Neuron-astrocyte co-cultures were assayed
for viability 48 hours after the 2nd MG132 hit. For astrocyte-conditioned media experiments,
astrocytes were treated with 1st MG132 hit for 24 hours. Astrocyte-conditioned media from
MG132 and vehicle-treated astrocytes were directly transferred (never frozen) to neocortical
neurons in a 1:1 dilution in neuronal media.
Dual-hit protocol The 1st MG132 hit or MG132 pretreatment was delivered as a 10x stock to
astrocytes that had been plated the day before. Following a 24-hour incubation in the 1st MG132
hit, the medium was removed and the 2nd MG132 hit or MG132 post-treatment was delivered at
a 1x concentration in a full media exchange, which served to remove all previously applied
MG132. After a 24-hour incubation in the 2nd MG132 hit, astrocyte viability was measured by
blinded counts of Hoechst-stained nuclei counts or ATP levels as described in the “Cell viability
and immunocytochemistry” and “ATP assay” sections, respectively. All experiments involved a
24-hour period between the 1st and 2nd MG132 hits and a 24-hour incubation between the 2nd
MG132 hit and the assay, with the exception of data presented in Figure 9D-I and Figure 9J-L.
MG132, N-acetyl L-cysteine, D-cysteine, and L-cysteine treatments Proteotoxic stress was
induced 24 hours after plating with the proteasome inhibitor MG132 (Cat. No. 474790, EMD
Millipore, Billerica, MA). MG132 was added at a final concentration of 0.1 to 0.8 µM in the
presence or absence of 3 mM NAC (Cat. No. 160280250, Acros, Geel, Belgium). On the
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following day, fresh NAC was added for an additional 24 h, after which cell viability was
assessed as described below. The same procedure was followed for studies on 3 mM L-cysteine
(Cat. No. C12, 180-0, Aldrich Chemical Company, Milwaukee, WI) and D-cysteine (Cat. No.
C1329, Tokyo Chemical Industry, Tokyo, Japan).
Pharmacological inhibitors Buthionine sulfoximine was used as a competitive inhibitor of the
rate limiting enzyme glutamate-cysteine ligase (Cat. No. 309475000, Acros) (Griffith & Meister,
1979). Ammonium chloride was used to inhibit all types of autophagy by increasing the
lysosomal pH (NH4Cl, 20 mM; Acros Organics, Somerset NJ). VER155008 (Cat. No. 3803,
Tocris Bioscience, Minneapolis, MN) was used as an ATPase activity inhibitor of Hsp70/Hsc70
(Chatterjee, et al., 2013; Massey, et al., 2010; Saykally et al., 2012). Pifithrin-µ (2phenylethynesulfonamide, Cat. No. 506155, EMD Millipore) was used to bind and inhibit the
substrate-binding domain of Hsp70/Hsc70 (Balaburski et al., 2013; Granato, et al., 2013;
Kondoh & Osada, 2013; Leu, et al., 2009; Leu, et al., 2011; Schlecht, et al., 2013). The third
Hsp70/Hsc70 inhibitor, MAL3-101 (provided by Drs. Peter Wipf and Jeffrey Brodsky),
interferes with Hsp40-mediated ATP hydrolysis by Hsp70/Hsc70 (Adam, et al., 2014; Braunstein
et al., 2011; Hatic, Kane, Saykally, & Citron, 2012; Huryn, et al., 2011; Kilpatrick et al., 2013).
Sodium benzoate (Cat. No. AC447802500, Acros) and used to inhibit the conversion between Dand L-cysteine by D-amino acid oxidase (Katane et al., 2013). Tin (IV) protoporphyrin IX
dichloride (SnPPx, Cat. no. Sn749-9, Frontier Scientific, Logan, Utah), competes for heme at the
heme oxygenase 1 active site and therefore inhibits the conversion of heme into bilirubin and
carbon monoxide (Drummond & Kappas, 1981; Yoshinaga, et al., 1982). Pharmacological
inhibitors were added at the same time as MG132 and NAC.
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Cell viability and immunocytochemistry Cell viability was measured following nuclear
staining with the Hoechst reagent. Upon the completion of the experiment, astrocytes were fixed
in 3% paraformaldehyde (Cat. No. 9990244, Thermo Scientific, Pittsburgh, PA) and 3% sucrose
(Cat. No. 0389, Sigma-Aldrich, St. Louis, MO) in phosphate buffer for 20 min at room
temperature and washed three times with 10 mM PBS. Cells were then stained with Hoechst
33258 (5 µg/mL, bisBenzimide, Sigma-Aldrich) diluted in PBS for 20 min. Images of Hoechststained nuclei were captured on an EVOS microscope (Model #AMF 4301 US, Advanced
Microscopy Group, Bothell WA) in the 3 o’clock and 9 o’clock position in each well. ImageJ
software (NIH Image, Bethesda, MD) was then used for blinded cell counts of the number of
Hoechst-stained nuclei at 200x magnification.
For immunocytochemistry, astrocyte cultures and neuron-astrocyte co-cultures were
washed in PBS, and blocked for 30 min in Odyssey Block (LI-COR Bioscience, Lincoln, NE)
diluted 1:1 in PBS. Primary antibodies were prepared in Odyssey Block/PBS (1:1) with 0.3%
Triton X-100 as indicated in Table 2. Cells were incubated in primary antibody solutions
overnight at 4 oC. On the following day, cells were washed three times with PBS. Secondary
antibodies (see Table 3) were diluted in 1:1 Odyssey Block/PBS and 0.3% Triton X-100 and
applied to cells for 1 hour at room temperature. Finally, the secondary antibody was removed by
three washes before microscopy on the EVOS microscope or LI-COR Odyssey Imager.
ATP assay ATP levels were measured by the luminescent CellTiter-Glo Assay with minor
modifications (Cat. no. G7572, Promega, Madison, WI), as previously published (Posimo et al.,
2014; Titler, et al., 2013). Astrocytes were lysed and incubated in CellTiter-Glo reagent at a 1:2
ratio in astrocyte cell culture medium (25 μL CellTiter-Glo: 50 μL media). Luminescence was
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measured on a luminometer (VICTOR3 1420 multilabel counter; PerkinElmer, Waltham, MA)
after a 15 min incubation period.
Total and reduced glutathione measures. The In-Cell Western technique was used to assess
total glutathione levels. Glutathione measures were expressed as a fraction of α-tubulin signal
and Hoechst- or DRAQ5-stained nuclei in the same well to account for differences in cell
density. Reduced glutathione levels were measured by the luminescent GSH-Glo assay according
to the manufacturer’s instructions (Cat. no. V6911, Promega, Madison, WI). Reduced
glutathione levels were expressed as a function of Hoechst-stained nuclei on parallel plates to
account for differences in cell density.
Immunoblotting. Whole cell lysates were collected in cell lysis buffer (recipe from Cell
Signaling Technologies, Danvers, MA, Cat. no. 9803) supplemented with protease inhibitor
cocktail (1:50; Cat. no. P8340, Sigma-Aldrich) and 10 mM sodium fluoride (Leak, Castro,
Jaumotte, Smith, & Zigmond, 2010), 24 h or 48 h following treatments. The samples were then
sonicated with a probe and protein concentrations were measured by the bichinchoninic assay.
Ten micrograms of each sample were loaded on a 10% polyacrylamide gels and subjected to
electrophoresis. Separated proteins were then transferred to Immobilon-FL polyvinylidene
fluoride or nitrocellulose membranes (EMD Millipore). Following the transfer, membranes were
subjected to three Tris-buffered saline (TBS) washes before the blocking step in 5% nonfat dry
milk in TBS or Odyssey block diluted 1:1 in TBS (Cat. no. 927-40000, LI-COR). Primary
antibodies (Table 2) were prepared in TBS with 0.1% Tween and 5% bovine serum albumin
fraction V (Research Products International, Mount Prospect, IL) or Odyssey block diluted 1:1 in
TBS with 0.1% Tween. Secondary antibodies (Table 3) were diluted in TBS with 5% nonfat dry
milk and 0.1% Tween or in Odyssey block diluted 1:1 in TBS with 0.1% Tween. Immunolabeled
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blots were then washed in TBS with 0.1% Tween and fluorescent signal was assessed on a LICOR Odyssey Imager. The data was quantified by Odyssey software (Ver 3.0; LI-COR) or
Image Studio Lite software (LI-COR).
Tissue collection for in vivo aging study Protocols for obtaining tissue in this study were
approved by the Duquesne University Institutional Animal Care and Use Committee and
conducted in compliance with the NIH Guide for the Care and Use of Laboratory Animals.
Female Sprague Dawley rats (Charles River, Wilmington, MA) were generated in an in-house
breeding colony and aged to 22 months. Animals were sacrificed by 22 months of age due to
poor health at older ages. Animals were anesthetized with 5% isoflurane immediately prior to
decapitation and tissue microdissection. The boundaries of the olfactory bulb, substantia nigra,
and striatum were defined according to the Paxinos rat atlas (George Paxinos, 1998). All animals
were sacrificed within 48 h of each other and processed together. In addition, three young female
rats (2-4 months old) were perfused with 4% paraformaldehyde for immunofluorescent staining
of heat shock proteins. Fixed brains were cryoprotected in 30% sucrose in phosphate-buffered
saline and cut at 40 microns on a freezing microtome (Microm HM450, Thermo Scientific,
Pittsburgh, PA) (Crum et al., 2015b; Gleixner et al., 2014).
Immunohistochemistry Coronal sections through the substantia nigra were immunolabeled with
Hsp25, Hsp60, and HO1 antibodies in conjunction with antibodies raised against the
dopaminergic phenotype marker tyrosine hydroxylase. All sections were blocked with Odyssey
Block diluted in 1:1 in PBS for 1h at room temperature. Sections were then incubated overnight
at 4oC in primary antibodies diluted in PBS with 0.3% Triton X-100. Unbound primary
antibodies were washed off with three exchanges of PBS before incubation in secondary
antibodies for 1hr at room temperature. After the secondary antibody incubations, tissue sections
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were washed, mounted onto glass slides, and coverslipped with Fluoromount-G (Cat. no. 010001, Southern Biotech, Birmingham, AL). A confocal microscope was used to examine protein
expression patterns (Leica TCS SP2, Wetzlar, Germany). For the primary and secondary
antibody dilutions and sources, please see Tables 2 and 3. The following controls were used for
each antibody examined by immunohistochemistry: 1) exposure to all solutions except both
primary antibodies and 2) exposure to one primary antibody only, followed by exposure to both
secondary antibodies (Crum, et al., 2015b).
Statistical analyses Statistical significance was determined with SPSS Statistics (IBM, Version
10.0, Armonk, NY) or GraphPad Prism (Version 6, La Jolla, CA) software. Data were subjected
once to the Grubb’s outlier test. For experiments with two groups, the Student’s t test was used
and for experiments with more than two groups a two- or three-way ANOVA with the
Bonferroni post hoc correction was employed. Each experiment was conducted on at least three
separate occasions. Furthermore, each experiment was conducted in triplicate or quadruplicate
wells. Triplicate or quadruplicate data were averaged for an n=1 only. For Western blotting
experiments, samples were collected on a minimum of three separate occasions. Changes were
only deemed significant when p 0.05. All data are presented as the mean  standard error of
the mean.
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Chapter 3 Results
3.1 Exposure to severe proteotoxic stress elicits tolerance in surviving astrocytes and
does not abolish their neuroprotective role
Part I.
Characterization of cortical astrocyte cultures
We began these studies by developing a model of proteotoxic stress in cortical
astrocyte cultures harvested from postnatal rat pup brains. In order to characterize the
purity of the cortical astrocyte cultures, cells were immunolabeled for glial markers glial
fibrillary acidic protein (GFAP) and S100β and stained with the nuclear marker Hoechst
(Fig 1a-d lower magnification, Fig 1e-h higher magnification). Large, Hoechst+ nuclei
stained positive for GFAP and S100β or for S100β alone (long-stemmed arrows),
whereas smaller nuclei were only GFAP+ (short-stemmed arrows). Shrunken, condensed
nuclei did not stain for either glial marker, perhaps because they were undergoing
apoptosis and lost the glial phenotype (Fig. 1g). The purity of the astrocyte cultures was
then determined by counting the number of GFAP+ cells, S100β+ cells, and cells that did
not stain for either glial cell marker, all expressed as a percentage of total Hoechst + cell
numbers. Primary cultures derived by the abovementioned protocol contained 83%
GFAP+ cells and 87% S100β+ cells, whereas 8% of the cells did not stain positive for
either astrocyte marker (Fig 1i).
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Figure 1. Cortical astrocyte culture
purity in Basal Medium Eagle. a-h
Astrocytes
were
immunocytochemically labeled for
S100β (a and e; green) and GFAP (b
and f; red) as well as stained for
nuclear marker Hoechst (c and g;
blue). The center of the image in a-d
was photographed at a higher
magnification
in
e-h.
Cellular
morphologies fell into three anatomical
categories. Cells with large, flat nuclei
were labeled with both S100β and
GFAP or only with S100β (longstemmed arrows, g). Cells with smaller
and brighter nuclei were positive for
GFAP only (short-stemmed arrow).
Condensed, fragmented nuclei lacked
both markers, perhaps because they
were apoptotic cells that lost their
normally glial phenotype (arrowhead).
i: Quantification of Hoechst-labeled
nuclei that were positive for either
GFAP (light gray bar) or S100β (dark
gray bar), or negative for either marker
(black
bar).
n=3
independent
experiments.
Reprinted from
“Astrocyte plasticity revealed by
adaptations to severe proteotoxic
stress,” by A. M. Titler, 2013, Cell
Tissue Research, 352, 427-443.
Copyright [2013] by A.M Titler.
Reprinted with permission.
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Proteotoxic stress elicits stress tolerance in astrocytes
Stress adaptations are often studied in the context of low-level or subtoxic
stressors. For example, exposure to subtoxic ischemic insults decreases astrocyte
susceptibility to subsequent ischemic insults, a phenomenon known as preconditioning or
stress tolerance (Pang et al., 2015). In contrast, severe stress is generally thought to
weaken cells and to exacerbate the toxic response to subsequent insults. We define severe
stress as stress that kills some fraction of the cellular population under study. Because
astrocytes are more resistant than many other types of brain cells, we hypothesized that
astrocytes surviving severe stress may mount adaptive defenses and tolerate subsequent
insults better than naïve astrocytes. If this hypothesis were supported, it would suggest
that stress can elicit protective and not always toxic stress responses even when the stress
is high in concentration. This hypothesis lies in contrast with traditional views of the
stress response, which hold that cells can only mount adaptive defenses against mild
stress (E. J. Calabrese, 2008).
In order to test whether astrocytes that survive high levels of proteotoxic stress
would be more or less susceptible to subsequent insults, we developed a dual hit model.
Proteotoxic stress, or stress associated with loss of protein homeostasis, was induced with
the proteasome inhibitor MG132. MG132 was chosen because proteotoxicity is a major
hallmark of all neurodegenerative disorders (Gundersen, 2010; Keller, Hanni, et al.,
2000a; Morimoto, 2008) and it is a well characterized and commonly used toxin (D. H.
Lee & Goldberg, 1998). Cortical astrocytes were first exposed to toxic concentrations of
MG132; this is referred to as the MG132 pretreatment. In order to assess the effect of the
initial MG132 insult, the surviving glial population was challenged a second time with

32

toxic concentrations of MG132 to see if the astrocytes were resistant to subsequent
insults. The second exposure to MG132 is referred to as the MG132 post-treatment.
Increasing concentrations of MG132 pretreatment elicited morphological changes
consistent with astrocyte stress reactivity, as visualized by increases in GFAP and S100β
immunostaining (Fig 2a). Similarly, increasing concentrations of MG132 post-treatment
led to cytoskeletal condensation and retraction of astrocytic processes (Fig 2b),
suggestive of cellular stress (Sofroniew & Vinters, 2010; Tynan et al., 2013).
Quantification of the number of Hoechst+ cells revealed that MG132 pre- and posttreatment alone led to a significant decrease in astrocyte viability (48h or 24h after
treatment, respectively) (Fig 2c & d). As expected, astrocytes that survived MG132
pretreatment were resistant to 60 and 80 µM MG132 post-treatment. In other words, there
was no additional decrease in viability in response to MG132 post-treatment when
astrocytes had been pretreated with MG132. However, previously stressed astrocytes
were unable to tolerate the toxicity associated with 160 µM MG132 post-treatment.
These data suggest that stressed astrocytes are resistant to subsequent insults but that
there is a threshold beyond which they no longer maintain tolerance. In order to
determine whether severe proteotoxic stress was eliciting significant loss in cell numbers
at the time of post-treatment, astrocyte viability was assessed 24h after MG132
pretreatment (Fig 2e). As expected, MG132 pretreatment (0.20-0.80 µM) significantly
decreased astrocyte viability at the time of MG132 post-treatment. Furthermore, there
was no significant difference in viability between 24 and 48h after MG132 pretreatment.
These findings suggest that the weaker astrocytes have already died at the time of
delivery of post-treatment and that there is no additional cell loss in the next 24h interval.
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Figure 2. Severe proteotoxic stress renders astrocytes protected against subsequent insults
a: Photomontage of GFAP, S100β and Hoechst labeled astrocytes following treatment with
indicated concentrations of MG132. MG132 was applied the day after plating (pretreatment or
1st hit paradigm). Two days later, cells were fixed, immunostained, and photographed. Cell loss
was apparent at concentrations of 0.2 µM and beyond. b: Photomontage of GFAP, S100β and
Hoechst labeled astrocytes following treatment with indicated concentrations of MG132. Cells
were treated with MG132 two days after plating (post-treatment or 2nd hit paradigm). Much
higher concentrations of MG132 (60 µM and beyond) were needed to elicit cell loss in the posttreatment paradigm, perhaps because cells had been plated 2 days before and were much better
attached. c: MG132 pretreatments and post-treatments were combined and viability assessed
with counts of Hoechst-positive nuclei. Increasing shades of gray indicate higher concentrations
of MG132 post-treatment. The lightest gray bars indicate pretreatment alone (0 µM MG132
post-treatment). d: A representative photomontage of cells treated with 0.4 µM pretreatment, 80
µM post-treatment, and the combination of both is shown on the right of the quantification. Cells
pretreated with an LC50 concentration of 0.4 µM MG132 were protected against additional loss
of nuclei when post-treated with a normally LC50 concentration of 80 µM MG132. e: Cells were
pretreated with indicated concentrations of MG132 and assayed either 24 h later or 48 h later for
viable nuclei. There was no difference in viability between cells collected at the two timepoints.
n=3 independent experiments. * p ≤ 0.05 versus MG132 pretreatment alone (0 µM posttreatment), + p ≤ 0.05 versus MG132 post-treatment alone (0 µM MG132 pretreatment), twoway ANOVA followed by Bonferroni post hoc test. Reprinted from “Astrocyte plasticity
revealed by adaptations to severe proteotoxic stress,” by A. M. Titler, 2013, Cell Tissue
Research, 352, 427-443. Copyright [2013] by A.M Titler. Reprinted with permission.

34

Stress tolerance is associated with preservation of metabolic function
ATP levels reflect metabolic health and are often used as an indicator of cell
viability (Crouch, Kozlowski, Slater, & Fletcher, 1993; Petty, Sutherland, Hunter, &
Cree, 1995; Unnithan, et al., 2012). Therefore, we used a luminescent assay for ATP
levels, CellTiter Glo, to complement the Hoechst cell count data. However, changes in
ATP did not precisely coincide with changes in the number of Hoechst+ nuclei in this
model, consistent with other reports from our group (Posimo, et al., 2014). For example,
ATP levels were not decreased by MG132 pretreatment alone as had been shown for
Hoechst+ cell numbers (Fig 3a). However, a concentration-dependent decrease in ATP
was observed in response to MG132 post-treatment in cells that had not been previously
stressed. In contrast, MG132-pretreated astrocytes showed no significant decrease in ATP
levels in response to MG132 post-treatment, except in the 0.10 µM pretreatment and 80
µM post-treatment groups. These data suggest that severe proteotoxic stress prevents the
loss of ATP in response to MG132 post-treatment, consistent with stress-induced
protection of metabolic function. In order to force ATP loss, we also applied 100-fold
higher MG132 pretreatment concentrations (Fig 3b). Even at these extremely high
concentrations of MG132 pretreatment (10 to 80 µM MG132; sufficient to yield ATP
loss), previously stressed astrocytes were able to maintain ATP levels in response to posttreatment (80 µM MG132).
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Figure 3. Impact of severe proteotoxic stress on ATP a: Viability following pretreatment and
post-treatment was assessed with the Cell Titer Glo assay for ATP. ATP levels did not fall with
pretreatment even though cell number was lower by parallel counts of Hoechst stained nuclei in
Figure 2. However, ATP levels did fall with post-treatment under control conditions (no
pretreatment). In contrast, cells that were pre-stressed with MG132 were protected against the
ATP loss caused by post-treatment. n=3 independent experiments. b: ATP assay following 10-fold
higher pretreatment concentrations of MG132 that did elicit ATP loss. Pretreated cells were
completely protected against the usual loss of ATP in response to 80 µM MG132. n=3
independent experiments. * p ≤ 0.05 versus MG132 pretreatment alone (0 µM post-treatment), + p
≤ 0.05 versus MG132 post-treatment alone (0 µM MG132 pretreatment), two-way ANOVA
followed by Bonferroni post hoc test. Reprinted from “Astrocyte plasticity revealed by adaptations
to severe proteotoxic stress,” by A. M. Titler, 2013, Cell Tissue Research, 352, 427-443.
Copyright [2013] by A.M Titler. Reprinted with permission.
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Severe proteotoxic stress leads to upregulation of cellular defenses
We hypothesized that high concentrations of MG132 would elicit proteotoxic
stress and the upregulation of cellular defenses. As an indicator of proteotoxicity, we
measured ubiquitin-conjugated proteins by Western blot analysis. Ubiquitin is attached to
misfolded proteins in order to tag them for proteasomal degradation (Lecker, et al.,
2006). Application of proteasomal inhibitors, such as MG132, is expected to elicit an
increase in ubiquitinated proteins because the tagged proteins can no longer be degraded.
In cells not exposed to MG132 pretreatment, MG132 post-treatment elicited a dramatic
increase in ubiquitin-conjugated proteins, demonstrating proteotoxic stress (Fig 4a).
Furthermore, there was an even greater increase in ubiquitin-conjugated proteins in
response to the dual hits. These findings suggest that astrocytes respond to MG132 posttreatment with a sharp increase in protein misfolding, and that this response is still
evident and even greater when cells have been previously exposed to MG132
pretreatment. Thus, previously stressed astrocytes are resistant to subsequent proteotoxic
insults despite evidence of severe proteotoxic stress. Importantly, the results also show
that previously stressed astrocytes are not simply refractory to the MG132 toxin and can
still respond to continued proteotoxic stress. For example, we have not simply enriched
our cultures in cells that fail to take up the MG132 toxin and so do not respond to the
post-treatment either. Further evidence that severely stressed astrocytes still respond to
post-treatment was gathered by measurements of HO1, which is known to be induced by
cellular stress and to engage in antioxidant defense (Fig 4b) (Schipper, et al., 2006;
Schipper, et al., 1998; Schipper, Song, Zukor, Hascalovici, & Zeligman, 2009). MG132
post-treatment elicited a dramatic increase in HO1 in MG132-pretreated astrocytes
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whether or not they had been exposed to MG132 pretreatment. Again, these results are
inconsistent with the notion that stressed astrocytes are refractory to further MG132
toxicity. These data also demonstrate that the stressed astrocytes mount active defenses
against protein misfolding stress. In sum, the HO1 and ubiquitin-conjugated proteins data
confirm that previously stressed astrocytes still take up MG132 and respond to posttreatment, but nevertheless resist additional cell death.
It has been known for many decades that the folding chaperone Hsp70 is
upregulated in response to protein misfolding stress (Mayer & Bukau, 2005). This was
also observed in our studies as MG132 post-treatment significantly increased Hsp70
levels (Fig 4c). However, MG132 pretreatment blunted the effect of MG132 posttreatment on Hsp70 levels. Similar to HO1 and Hsp70, GFAP is a highly stressresponsive protein (Middeldorp & Hol, 2011). As an additional measure of cellular stress
in our model, we investigated the effect of MG132 pre- and post-treatment on GFAP
levels. MG132 pretreatment significantly increased GFAP as expected (Fig 4d). No
additional effect of post-treatment on GFAP was observed in pretreated cells. These
results show that the impact of post-treatment on two stress-responsive proteins, Hsp70
and GFAP, is blunted by pretreatment.
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Figure 4. Severe proteotoxic stress elicits the upregulation of protein defenses. Western
immunoblotting on astrocytes treated with 0.4 µM MG132 pretreatment, 80 µM MG132 posttreatment, and the combination of two hits. Representative infrared images of protein bands
were pseudocolored red or green and are shown adjacent to the quantification (see arrows) for
ubiquitin-conjugated proteins (a, n=6 independent experiments), heme oxygenase 1 (b, HO-1;
n=6 independent experiments), heat shock protein 70 (c, Hsp70, n=6 experiments), and GFAP
(d, n=3 independent experiments). Gray bars indicate 0 µM MG132 post-treatment. Black bars
indicate 80 µM MG132 post-treatment. All proteins are expressed as a fraction of cytoskeletal
β-actin levels. * p ≤ 0.05 for 0 µM versus 80 µM MG132 post-treatment, + p ≤ 0.05 versus
MG132 post-treatment alone (0 µM MG132 pretreatment), two-way ANOVA followed by
Bonferroni post hoc test. Reprinted from “Astrocyte plasticity revealed by adaptations to
severe proteotoxic stress,” by A. M. Titler, 2013, Cell Tissue Research, 352, 427-443.
Copyright [2013] by A.M Titler. Reprinted with permission.
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Autophagy inhibition does not reduce stress tolerance in astrocytes
Autophagy is an alternative clearance system that removes misfolded proteins and
damaged organelles (Arias & Cuervo, 2011). Proteasome inhibition is known to
upregulate autophagy as a compensatory response (Ding et al., 2007; Korolchuk,
Menzies, & Rubinsztein, 2010). This raises the possibility that stressed astrocytes can
tolerate subsequent MG132 post-treatment because they transition from protein
degradation by the UPS to autophagy at times of UPS inhibition. Thus, astrocytes were
stained for a marker of chaperone-mediated autophagy, LAMP2a (Fig 5a-d) (Kaushik &
Cuervo, 2012). Qualitative assessments of LAMP2a levels reveal that this protein was
increased in the dual hit group. This suggests that stressed astrocytes may upregulate
autophagic systems to defend against subsequent proteotoxic stress. Therefore, we
inhibited all forms of autophagy with ammonium chloride and assessed astrocyte
viability (R. Sun et al., 2015). However, inhibition of autophagy did not decrease the
stress-induced resilience in our model (Fig 5e). These findings suggest that stressed
astrocytes do not rely on autophagy for stress tolerance.
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Figure 5. Astrocytes do not rely on
autophagy
for
resilience.
a-d
Immunocytochemistry
for
lysosomeassociated membrane protein type-2a
(LAMP2a, red) in astrocytes treated with 80
µM MG132 post-treatment (b), 0.4 µM
MG132 pretreatment (c), and the
combination of two hits (d). Nuclei were
stained with Hoechst (blue). LAMP2a was
found in a perinuclear anatomical location,
as expected from a lysosomal marker, and
was highest in the astrocytes treated with
two hits (0.4 µM pretreatment + 80 µM
post-treatment). e: Nuclear viability of
astrocytes treated with 0.4 µM MG132
pretreatment, 80 µM MG132 post-treatment,
and the combination of two hits, in the
presence or absence of autophagy inhibitor
ammonium chloride (20 mM NH4Cl). Gray
bars indicate 0 µM MG132 post-treatment.
Black bars indicate 80 µM MG132 posttreatment. Pretreated astrocytes did not
respond to post-treatment with additional
cell loss and NH4Cl had no effect on this
pattern. n=3 independent experiments. * p ≤
0.05 for 0 µM versus 80 µM MG132 posttreatment, + p ≤ 0.05 versus MG132 posttreatment
alone
(0
µM
MG132
pretreatment), two-way ANOVA followed
by Bonferroni post hoc test. Reprinted from
“Astrocyte plasticity revealed by adaptations
to severe proteotoxic stress,” by A. M.
Titler, 2013, Cell Tissue Research, 352, 427443. Copyright [2013] by A.M Titler.
Reprinted with permission.
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Inhibition of glutathione synthesis attenuates stress tolerance in astrocytes
Glutathione is one of the most abundant cellular antioxidants and astrocytes are
the primary source of glutathione in the brain (Dringen, 2000; Makar et al., 1994; Slivka,
Mytilineou, & Cohen, 1987). In Parkinson’s disease, astrocytes retain and/or upregulate
glutathione levels despite loss of glutathione in neighboring neurons (Damier, et al.,
1993; Mythri, et al., 2011). Therefore, we hypothesized that astrocytes rely on
glutathione to defend against severe proteotoxic stress. In order to test the importance of
glutathione in the dual hit model, glutathione synthesis was inhibited with buthionine
sulfoximine (BSO) (Griffith, 1982; Griffith & Meister, 1979). BSO successfully
decreased total glutathione levels at subtoxic concentrations (Fig 6a-c). MG132
pretreatment completely prevented the loss of total glutathione in response to MG132
post-treatment, suggesting that stressed astrocytes may rely on glutathione to survive a
second challenge and BSO abolished this effect (Fig 6d-f). As expected, loss of
glutathione sensitized MG132-pretreated astrocytes to MG132 post-treatment. In other
words, previously stressed astrocytes showed a 42% decrease in viability in response to
MG132 post-treatment under conditions of glutathione loss (Fig 7a-i). This suggests that
stressed astrocytes rely on glutathione synthesis to tolerate subsequent MG132 insults.
BSO did not alter ATP levels in stressed astrocytes (Fig 7j). Thus, ATP levels again
failed to coincide with the number of Hoechst+ nuclei.
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Figure 6. Buthionine sulfoximine attenuates the rise in glutathione with proteotoxic stress. a
Impact of buthionine sulfoximine (BSO), an inhibitor of glutathione (GSH) synthesis, on glutathione
levels (expressed as a fraction of cytoskeletal α-tubulin levels; gray bars) and on nuclear viability
(black bars). n=3 independent experiments. Representative images of Hoechst-stained nuclei treated
with indicated concentrations of buthionine sulfoximine are illustrated in b. Representative infrared
images of the glutathione assay (pseudocolored green) and α-tubulin levels (pseudocolored red) are
shown in c. From these data, the 12.5 µM buthionine sulfoximine concentration was chosen for
subsequent experiments because it reduced glutathione levels without causing any cell death. d:
Glutathione levels (expressed as a fraction of α-tubulin) in astrocytes treated with 0.4 µM MG132
pretreatment, 80 µM MG132 post-treatment, and the combination of two hits, in the absence or
presence of 12.5 µM buthionine sulfoximine. Gray bars indicate 0 µM MG132 post-treatment. Black
bars indicate 80 µM MG132 post-treatment. Glutathione levels fell with 80 µM MG132 posttreatment, but were completely rescued by pretreatment with 0.4 µM MG132 in the absence of
buthionine sulfoximine. In the presence of buthionine sulfoximine, glutathione levels were depressed
in all groups except the 80 µM post-treatment alone group. n=3 independent experiments.
Representative infrared images of glutathione (green) and α-tubulin levels (red) are shown in e and f,
respectively. * p ≤ 0.05 0 µM versus 80 µM MG132 post-treatment, + p ≤ 0.05 versus MG132 posttreatment alone (0 µM MG132 pretreatment), and ^ p ≤ 0.05 versus 0 µM buthionine sulfoximine
(H2O vehicle), two-way ANOVA followed by Bonferroni post hoc test. Reprinted from “Astrocyte
plasticity revealed by adaptations to severe proteotoxic stress,” by A. M. Titler, 2013, Cell Tissue
Research, 352, 427-443. Copyright [2013] by A.M Titler. Reprinted with permission.
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Figure 7. Stressed astrocytes rely on glutathione in order to remain resilience. a
Nuclear viability in astrocytes treated with 0.4 µM MG132 pretreatment, 80 µM
MG132 post-treatment, and the combination of two hits, in the absence or presence of
12.5 µM buthionine sulfoximine. Gray bars indicate 0 µM MG132 post-treatment.
Black bars indicate 80 µM MG132 post-treatment. Buthionine sulfoximine rendered
pretreated cells sensitive to 80 µM MG132 post-treatment, as they were no longer
protected against additional cell loss. n=4 independent experiments. b-i:
Representative images of Hoechst-stained nuclei in astrocytes treated with 0.4 µM
MG132 pretreatment, 80 µM MG132 post-treatment, and the combination of two hits,
in the absence or presence of 12.5 µM buthionine sulfoximine. Note the enhancement
of the toxicity of two hits in the presence of buthionine sulfoximine. j: ATP levels of
astrocytes treated in the same format as in a. Astrocytes were still protected against
additional ATP loss even in the presence of buthionine sulfoximine. n=3 independent
experiments. * p ≤ 0.05 0 µM versus 80 µM MG132 post-treatment, and + p ≤ 0.05
versus MG132 post-treatment alone (0 µM MG132 pretreatment), two-way ANOVA
followed by Bonferroni post hoc test. Reprinted from “Astrocyte plasticity revealed
by adaptations to severe proteotoxic stress,” by A. M. Titler, 2013, Cell Tissue
Research, 352, 427-443. Copyright [2013] by A.M Titler. Reprinted with permission.
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Part II.
Our next set of dual hit studies was conducted at a lower plating density due to
rapid cell growth and in a less expensive cell culture medium. Therefore, astrocyte
cultures were reevaluated in this new model, in collaboration with an undergraduate
student, Deepti Pant. Astrocyte culture purity was slightly higher with the new protocol:
89.6% of the cells were GFAP+, 91.8% were S100β+, and 6.1% of the cells did not stain
positive for either marker (Fig 8). As described in Part I, viable astrocytes were
quantified by measuring the number of Hoechst+ cells. In the dual hit studies of Part II we
used the automated cell counting function in ImageJ software (NIH Image). Hoechst +
cells undergoing cell death typically display shrunken, condensed nuclei. Therefore,
Hoechst+ nuclei with areas less than 350 pixels (53 µm2) were excluded in the viability
measurements. Representative images of such cells are illustrated in Figure 8C &D.
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Figure 8. Cortical astrocyte culture
purity in Dulbecco’s Modified Eagle
Medium. A) Cortical astrocytes were
stained with the nuclear marker
Hoechst and immunolabeled for the
glial markers glial fibrillary acid
protein (GFAP) and S100β. B) The
percentage of Hoechst+ cells that were
immunolabeled for GFAP or S100β
proteins or were immunonegative were
quantified. C) Representative image of
Hoechst-stained nuclei in untreated
astrocytes. White arrow points to one
cell with a condensed nucleus. D) The
image in C was converted to a binary
image using the threshold function in
Image J. Nuclear cross-sectional areas
appear next to each cell in square
microns. Cells with nuclear areas
under 350 pixels (53 µm2, see black
arrow) were excluded from the counts
of viable cells in subsequent figures.
Reprinted from “Astrocytes surviving
severe stress can still protect
neighboring neurons from proteotoxic
stress,”
by
A.
M.
Gleixner,
2015, Molecular Neurobiology, Epub
ahead of print. Copyright [2015] by
A.M Gleixner. Reprinted
with
permission.
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Long-lasting stress tolerance in astrocytes
In addition to reevaluating astrocyte cultures with the new protocol, the LC50
concentrations of MG132 also had to be reevaluated. For the sake of simplicity, we
changed the name of the pretreatment to the 1st MG132 hit and the post-treatment to the
2nd MG132 hit. Toxic 1st and 2nd MG132 hit concentrations first had to be identified in
the new dual hit protocol. Despite several protocol modifications, toxic concentrations of
the 1st hit (0.16-0.64 µM) still elicited tolerance against a toxic 2nd hit (3.125 µM) (Fig
9A-C). The 2nd hit concentration in these studies was lower than that used in the Part I
dual hit studies. However, both MG132 concentrations decreased astrocyte viability by
approximately 50% in previously naïve cells. When we expressed the data from Fig 9A
as a function of the 0 µM 2nd MG132 hit (i.e., all gray bars were expressed as a
percentage of the adjacent black bars), the attenuation of the toxicity of the 2 nd hit in
previously stressed astrocytes became evident (Fig 9B). Consistent with the MG132 data,
astrocytes surviving toxic concentrations of a different proteasome inhibitor, lactacystin,
were also resistant to subsequent lactacystin insults (Fig 10). Lactacystin and MG132
have distinct mechanisms of action, although both converge on the chymotrypsin-like
activity of the proteasome particle and increase the cellular burden of misfolded proteins
(D. H. Lee & Goldberg, 1998).
In order to determine whether the effect of the 1st MG132 hit on the 2nd MG132
hit was long lasting, the duration between the 1st and 2nd hit was increased from 24h to
48h (Fig 9D-F) and 96h (Fig 9G-I). Astrocytes that survived the toxic 1st hit remained
protected against the 2nd hit for up to 96 hours. These findings suggest that the 1st hit does
not elicit transient protective effects. In addition, we also examined the duration of the

47

protective effect by increasing the interval between the 2nd hit and the time of viability
assay from 24 to 72h. As expected, astrocytes exposed to two severe proteotoxic insults
remained viable for up to 72h after the 2nd hit (Fig 9J-L). All of these findings are
consistent with the notion that stress-induced tolerance in this model is not fleeting in
nature.
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Figure 9. Severe proteotoxic
stress preconditions astrocytes
against subsequent insults. A)
Cortical astrocytes were treated
with indicated concentrations of
the proteasome inhibitor MG132
one day after plating (1st hit) or an
equal v/v of vehicle. Twenty-four
hours later, astrocytes were
challenged with a 2nd hit of
MG132 (3.125 M) or vehicle.
Astrocyte viability was assessed
24h after the 2nd hit by counting
viable Hoechst+ nuclei in blinded
fashion. B) Data in panel A were
expressed as a percentage of each
0 M 2nd MG132 hit group (i.e.,
each gray bar was expressed as a
percentage of the adjacent black
bar). C) Representative images of
Hoechst-stained astrocyte nuclei
from the groups shown in A. The
interval between the 1st hit and the
2nd hit was prolonged to 48h in DF and to 96h in G-I. E and H
represent data in D and G,
respectively, expressed as a
percentage of the 0 M 2nd
MG132 hit group. Representative
Hoechst-stained nuclei are shown
in F and I. J-K) The interval
between the 2nd hit and the assay
was extended to 72h. The data in
panel J were expressed as a
percentage of the 0 M 2nd
MG132 hit group and presented in
panel K. L) Representative
images of Hoechst-stained nuclei
from groups shown in J. * p ≤
0.05, ** p ≤ 0.01, *** p ≤ 0.001
vs 0 M 2nd MG132 hit, + p ≤
0.05, ++ p ≤ 0.01, +++ p ≤ 0.001
vs 0 M 1st MG132 hit, two-way
ANOVA followed by Bonferroni
post
hoc
correction.
Reprinted from
“Astrocytes
surviving severe stress can still
protect neighboring neurons from
proteotoxic stress,” by A. M.
Gleixner,
2015, Molecular
Neurobiology, Epub ahead of
print. Copyright [2015] by A.M
Gleixner.
Reprinted
with
permission.
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Figure 10. Lactacystin-mediated severe proteotoxic stress preconditions astrocytes
against subsequent insults. A) Five days after plating, astrocytes were treated with various
concentrations of lactacystin or an equivalent v/v of vehicle (phosphate buffered saline) as the
1st hit. On the following day, the astrocytes were treated with vehicle or a 2nd hit of
lactacystin at the indicated concentrations. Viability was assayed 24h after the 2nd hit by
counting Hoechst-stained nuclei. B) Representative images of Hoechst-stained nuclei for
experiments shown in panel A. * p ≤ 0.05 vs 0 M 2nd lactacystin hit; + p ≤ 0.05, ++ p ≤
0.01, +++ p ≤ 0.001 vs 0 M 1st lactacystin hit, two-way ANOVA followed by Bonferroni
post hoc correction Reprinted from “Astrocytes surviving severe stress can still protect
neighboring neurons from proteotoxic stress,” by A. M. Gleixner, 2015, Molecular
Neurobiology, Epub ahead of print. Copyright [2015] by A.M Gleixner. Reprinted with
permission.
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Astrocytes surviving the 1st hit do not exhibit characteristics of apoptosis
Hoechst or DAPI-stained cells undergoing apoptosis are often characterized by
increased staining intensity and condensed nuclear area relative to non-apoptotic cells
(Tone et al., 2007; Yu et al., 2002). Thus, we assessed nuclear area and staining intensity
in astrocytes treated with 1st, 2nd, and dual MG132 hits in order to determine if the 1st hit
left behind nuclear profiles exhibiting signs of cell death. The frequency distribution of
the number of cells corresponding to specific nuclear sizes is shown in Figure 11A-C. No
decrease in median nuclear size was found with the 1st, 2nd, or dual MG132 hits,
supporting the view that most apoptotic cells had died and washed off the plate at the
time of the viability assays. However, a slight decrease in average nuclear size was
observed in astrocytes exposed to dual MG132 hits, even when excluding cells with
nuclear areas less than 53 µm2 (Fig 11D & E). Representative images of Hoechst-stained
nuclei are shown in Figure 11F. Similar to the nuclear area analysis, no shift in median
nuclear staining intensity was observed in astrocytes treated with 1st, 2nd and dual MG132
hits (Fig 11G-I). Furthermore, no change in average nuclear staining intensity with 1st,
2nd, and dual MG132 hits was observed either. These findings suggest that cells
undergoing dual hits show a slight decrease in nuclear area but not staining intensity, but
that the effect size is very small. Most importantly, these measurements reveal that cells
surviving the 1st hit alone have viable nuclei with no change in average nuclear size.
As mentioned above, cells undergoing apoptosis are often described as having
shrunken nuclei with increased Hoechst staining intensity (Tone, et al., 2007). Therefore,
we assessed the relationship between nuclear size and Hoechst-staining intensity in the 1st
hit, 2nd hit, and both hit groups. According to the scatterplots, MG132 treatment
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eliminated a population of cells with small brightly stained nuclei [nuclear size 50-150
µm2 and nuclear staining intensity greater than 20 arbitrary units (A.U.) for the mean gray
value measurements] (Fig 11L-O). Therefore, we compared the effect of MG132 on the
small, brightly stained nuclei to the effect of MG132 on cells with large nuclei (larger
than 150 µm2). MG132 eliminated a greater percentage of Hoechst-stained nuclei in the
small, brightly stained nuclei group relative to the larger nuclei group (Fig 11P). These
data are normalized to the vehicle group because the number of nuclei in the large nuclei
group is significantly greater than the number of nuclei in the small, brightly stained
nuclei group. The raw, untransformed data that show these differences are illustrated in
Figure 12. Thus, small, brightly stained nuclei are most vulnerable to proteotoxic stress,
as might be expected because they already show signs of injury.
Double-stranded DNA breaks are indicative of cells undergoing apoptosis. The
TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) stain is a wellestablished marker of apoptosis (Elmore, 2007; Gavrieli, Sherman, & Ben-Sasson, 1992).
Terminal deoxynucleotidyl transferase incorporates fluorescently labeled dUTP onto the
exposed 3’-OH ends of the double-stranded DNA breaks in apoptotic cells. We counted
the number of TUNEL+ cells in our dual hit model in order to determine the number of
cells undergoing apoptosis at the time that our viability assays were conducted. Less than
10% of the total number of cells present at the time of fixation (24h after the 2nd hit) were
TUNEL+ in the 2nd MG132 hit group (Fig 11Q). The 0.16 µM 1st MG132 hit did not elicit
any increase in the number of TUNEL+ cells by itself in comparison to the 0 µM 1st
MG132 hit. The 1st hit also did not change the number of TUNEL+ cells in response to
the 2nd MG132 hit. Due to very low numbers of TUNEL+ cells, there was high inter-
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experimental variability of the data. Thus, we also expressed the number of TUNEL+
cells as a fold change over control values. Here we found that both naïve and stressed
astrocytes showed a significant increase in TUNEL staining in response to the 2nd
MG132 hit (Fig 11R). Representative images of TUNEL+ cells are displayed in Figure
11S. It is noteworthy that the number of TUNEL+ profiles was low at the time of the
assay, suggesting that we are mostly counting live cells at the time that our viability
assays are conducted. Furthermore, our data confirm that the 1st hit does not increase the
number of TUNEL+ profiles in response to the 2nd hit, suggesting that cell death is not
enhanced despite a slight shrinkage of nuclear surface area in the dual hit group. In sum,
these data are consistent with the analyses of nuclear size and Hoechst-staining intensity
and demonstrate that the 1st hit does not increase vulnerability to the 2nd hit when
measuring either live or dead cells because the fold change in TUNEL+ cells is similar
between naïve and stressed cells. It is important to note that by far the majority of cells
that we are counting in the dual hit group are not TUNEL+ and that they continue to
survive for at least 72h after the 2nd hit is administered (see Figure 9J-L), suggesting that
they are indeed survivors despite a slight decrease in average nuclear size. It is also
important to note that the TUNEL stain labels small, dying cells that are excluded from
our viable cell counts by the threshold function in ImageJ anyway. From the scatterplots
in Figure 11O it is further evident that the dual hits kill the brightest, smallest cells (0-150
microns in size) and that the majority of remaining cells are clustered around nuclear
sizes of 150 to 300 microns instead of a wider spread from 0 to 400 microns in the
untreated group (Figure 11L). The clustering of cells in the scatterplot data readily
explain the small decrease in average nuclear size in the dual hit group Figure 11E and
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the lack of change in median nuclear area in the dual hit group in Figure 11C. The
clustering effect is also apparent in the shape of the dual hit histogram in Figure 11C.
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Figure 11. See below for figure legend
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Figure 11. Nuclear viability in stressed astrocytes. Astrocytes were treated with the indicated
concentrations of MG132 24h (1st hit) and 48h (2nd hit) after plating. On the third day, astrocytes
were stained with the nuclear marker Hoechst and analyzed by a blinded observer using ImageJ
software. A-C) Frequency distributions of the number of nuclei corresponding to the indicated
nuclear area. The vehicle-treated group is included on all three figures for comparison. D) Average
nuclear size of all cellular profiles. E) Average size of all nuclei except those smaller than 53 µm2.
F) Representative high-power image of Hoechst-stained nuclear profiles. G-I) Frequency
distribution of the number of nuclei as a function of Hoechst nuclear staining intensity. The
vehicle-treated group is included on all three figures for comparison. J) Average nuclear staining
intensity of all cellular profiles. K) Average nuclear staining intensity of all profiles except cells
with nuclei smaller than 53 µm2. L-O) Nuclear staining intensity as a function of nuclear size. P)
Astrocytes were divided into two groups: those with small, bright nuclei (50-150 µm2; staining
intensity greater than 20 arbitrary units for the mean gray value measurements) or large nuclei
(greater than 150 µm2; all staining intensities). Raw data is presented in Figure 12. Q) Number of
TUNEL+ cells relative to the total number of Hoechst + nuclei. R) Data presented in panel Q were
expressed as a function of the 0 M 2nd MG132 hit groups. S) Representative images of TUNEL
staining. * p ≤ 0.05, ** p ≤ 0.01 vs 0 M 2nd MG132 hit; + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001
vs 0 M 1st MG132 hit; ^ p ≤ 0.05, ^^ p ≤ 0.01 vs small, bright nuclei; two- or three-way
ANOVA followed by Bonferroni post hoc correction. Reprinted from “Astrocytes surviving
severe stress can still protect neighboring neurons from proteotoxic stress,” by A. M. Gleixner,
2015, Molecular Neurobiology, Epub ahead of print. Copyright [2015] by A.M Gleixner.
Reprinted with permission.
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Figure 12. MG132 treatment is more lethal to small, bright nuclei
than large nuclei. A) Hoechst-stained nuclei were categorized into
two groups: those exhibiting small, brightly stained nuclei (50-150
µm2 in size and staining intensity greater than 20 arbitrary units for
the mean gray value measurements) or large nuclei (greater than 150
µm2; all staining intensities). Raw counts of the numbers of nuclei per
microscopic field of view (200× magnification) are shown here to
supplement the transformed data in Figure 3P. * p ≤ 0.05, ** p ≤ 0.01
vs 0 M 2nd MG132 hit; ++ p ≤ 0.01 vs vs 0 M 1st MG132 hit; ^^ p ≤
0.01, ^^^ p ≤ 0.001 vs small, bright nuclei, three-way ANOVA
followed by Bonferroni post hoc correction. Reprinted from
“Astrocytes surviving severe stress can still protect neighboring
neurons from proteotoxic stress,” by A. M. Gleixner, 2015, Molecular
Neurobiology, Epub ahead of print. Copyright [2015] by A.M
Gleixner. Reprinted with permission.
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Severe proteotoxic stress increases the expression of multiple defensive proteins
As we had switched protocols, we reexamined ubiquitinated protein and Hsp70
levels after dual hits in the new model in order to assess the effect of severe
proteotoxicity on astrocytes. A significant increase in ubiquitinated proteins was
observed 24h after the 1st MG132 hit, at the time of delivery of the 2nd hit (Fig 13A).
These findings confirm that the 1st hit elicits proteotoxic stress. Forty-eight hours after the
1st hit, there was no significant difference in the levels of ubiquitinated proteins between
the 0 and 0.16 µM 1st MG132 hit groups, supporting the view that the increase in
ubiquitinated proteins was transient. Furthermore, the 2nd MG132 hit elicited a significant
increase in ubiquitinated proteins in both naïve and stressed astrocytes 24h later (Fig
13B). Unlike in our initial studies (see Fig 4a), the two hits of MG132 were not
synergistic in their impact on ubiquitinated protein levels, perhaps because the
concentrations of MG132 were much lower in the new model. Nevertheless, these
findings are still consistent with the hypothesis that previously stressed astrocytes are not
simply refractory to the effects of MG132 and still respond to proteasomal inhibition by
the 2nd hit with a dramatic increase in ubiquitin-conjugated proteins. The transient
increase in ubiquitinated proteins after the 1st hit is also not consistent with the view that
the MG132 survivors do not even take up the MG132 poison or are refractory to its
effects.
Next we examined heat shock protein levels after the 1st hit. Depending upon the
heat shock protein examined, the 1st MG132 hit yielded varying effects on protein levels
24h after treatment (Fig 13C-L). Some heat shock proteins, such as pHsp27 and Hsp70,
were significantly upregulated 24h after the 1st MG132 hit. Trends towards increases in
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Hsp40 (p = 0.093), HO1 (p = 0.058), and Hsc70 (p = 0.070) were also observed 24h after
the 1st MG132 hit. However, several other defensive proteins were not altered by the 1st
MG132 hit (DJ-1, Hsp27, Hsp90 and Hip). Similar to the ubiquitinated protein pattern,
Hsp70 and HO1 were significantly increased by the 2nd MG132 hit in both naïve and
stressed astrocytes (Fig 13M & N). These findings suggest that astrocytes can still mount
defenses against subsequent proteotoxic insults despite prior exposure to severe stress.
Another important finding is that there is an increase in Hsp70 24h after the 1st hit alone
(Figure 13L) that wanes within 48h (or 24h after the 2nd hit in Figure 13M). Thus, the 1st
hit elicits a transient rise in Hsp70 as shown with the ubiquitin data. This finding suggests
that the 1st hit elicits active defenses in the cells that manage to survive and is not
consistent with the view the 1st hit simply leaves behind cells that have higher expression
of protective proteins to begin with and do not respond with any additional adaptive
changes in response to MG132. In conclusion, our data show that stressed astrocytes that
survive the 1st hit are not simply refractory to the MG132 poison and respond actively to
proteotoxicity, otherwise there could not be a transient rise in Hsp70
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Figure 13. MG132 increases protein misfolding stress and upregulates Hsp70 and HO1
levels. Astrocytes were treated with indicated concentrations of MG132 (1 st hit) and probed for
a number of stress-sensitive proteins 24h later (A, C-L). Astrocytes were treated with single or
dual hits of MG132 and assayed for levels of ubiquitinated proteins and heat shock proteins
Hsp70 and HO1 24h after the 2nd hit (B, M-N). *** p ≤ 0.001 vs 0 M 2nd MG132 hit, + p ≤
0.05, ++ p ≤ 0.01 vs 0 M 1st MG132 hit, two-way ANOVA followed by Bonferroni post hoc
correction for B, M, and N. The one-tailed, paired Student’s t-test was used for A, C-L.
Reprinted from “Astrocytes surviving severe stress can still protect neighboring neurons from
proteotoxic stress,” by A. M. Gleixner, 2015, Molecular Neurobiology, Epub ahead of print.
Copyright [2015] by A.M Gleixner. Reprinted with permission.
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Glutathione but not Hsp70 defenses are essential for stress tolerance in astrocytes
Thus far, we showed that the 1st MG132 hit upregulates Hsp70 levels at 24h, at
the time of delivery of the 2nd MG132 hit. Hsp70 overexpression has been shown to
increase glutathione peroxidase and reductase activity (Guo, et al., 2007), and our
previous study had shown that glutathione is essential for stress tolerance in astrocytes
(Titler, et al., 2013). Therefore, we hypothesized that Hsp70 may contribute to the
protective effects of glutathione in stressed astrocytes. Thus, we inhibited Hsp70 and
glutathione defenses both individually and together. Our results were not consistent with
the hypothesis that Hsp70 mediates tolerance in our model because a pharmacological
inhibitor of Hsp70, VER155008, did not alter the resistance of previously stressed
astrocytes to subsequent proteotoxic insults (Fig 14A-C). However, as observed
previously, glutathione synthesis inhibition by BSO did attenuate resistance to the 2nd
MG132 hit in previously stressed astrocytes. Simultaneous inhibition of Hsp70 activity
and glutathione synthesis elicited a significant decrease in basal viability (as observed
with VER155008 alone) and increased susceptibility of previously stressed astrocytes to
a 2nd MG132 hit (as observed with BSO alone; Fig 14A). As expected, when the data are
expressed as a function of the 0 µM 2nd MG132 hit group, they reveal increased
susceptibility of previously stressed astrocytes to the 2nd hit in the presence of BSO but
not VER155008 (Fig 14B). Figure 14C shows representative images of Hoechst-stained
cells corresponding to the data presented in Figure 14A. These findings reveal that
glutathione loss unmasks the toxic impact of the 2nd hit and are not consistent with the
hypothesis that the astrocytes surviving the 1st hit of MG132 are simply refractory to any
of its effects. In other words, if there were no defenses against MG132 in the surviving
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astrocytes, they would not become vulnerable to MG132 upon loss of glutathione
defenses.
Because glutathione was an important mediator of stress tolerance in our model,
we measured total glutathione levels and found that the 2nd MG132 hit significantly
increased glutathione (Fig 14D). There was also a trend towards an increase in the 1 st hit
group (p = 0.059). Total glutathione levels were even higher when Hsp70 activity was
inhibited by VER155008. Therefore, Hsp70 may not be a positive regulator of
glutathione synthesis in our model, but may reduce the need for this antioxidant. As
expected, BSO attenuated the effect of MG132 on total glutathione levels (Fig 14D & E).
The assay for total glutathione levels measures both the reduced and oxidized forms of
the thiol tripeptide. However, glutathione exists primarily in the reduced state (Owen &
Butterfield, 2010), which suggests that total glutathione measures are likely to coincide
with the reduced glutathione levels. To confirm this, reduced glutathione levels were
measured by the GSH-Glo assay. Twenty-four hours after delivery of the 1st MG132 hit
(or at the same time point as the 2nd hit delivery) reduced glutathione was significantly
increased intracellularly but not in the extracellular space (Fig 14F & G, respectively).
Forty-eight hours after the 1st hit, the 1st and 2nd MG132 hits alone significantly increased
intracellular reduced glutathione levels. No additional increase in reduced glutathione
was observed in the dual hit group (Fig 14H). These results are consistent with the view
that feedback inhibition on the rate limiting enzyme glutamate cysteine ligase prevents
any additional rise in glutathione levels in response to dual hits (C. S. Huang, Chang,
Anderson, & Meister, 1993). No additional increase may be evident after the 2nd MG132
hit because the 1st hit has already upregulated those defenses and there is no further need
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for a stress-induced rise in antioxidant defenses. The pattern of glutathione measurements
was similar for the In-Cell Western and GSH-Glo assays, as expected, suggesting that
most glutathione is in the reduced form.
In order to understand how glutathione defenses may be boosted in stressed cells,
glutamate cysteine ligase levels were examined by Western blot analysis. Glutamate
cysteine ligase is comprised of two subunits: the catalytic and modifier subunits.
Glutamate cysteine ligase modifier subunit (GCLM) levels were elevated 24h after the 1st
MG132 hit (Fig 14I). However, no significant increase was observed in glutamate
cysteine ligase catalytic subunit levels (Fig 15A). GCLM has been shown to increase the
catalytic efficiency of GCLC (Franklin, et al., 2009). Therefore, higher GCLM levels
may be sufficient to permit an increase in glutathione synthesis. We also measured a third
glutathione enzyme, glutathione S-transferase, which eliminates xenobiotics. The class of
glutathione S-transferase enzymes is divided according to the composition of their Nterminal domain (Mazzetti, et al., 2015). Glutathione S-transferase π and µ have both
been identified in astrocytes (Abramovitz et al., 1988; Cammer & Zhang, 1993; Johnson,
el Barbary, Kornguth, Brugge, & Siegel, 1993). Therefore, we assessed the effect of 1st
MG132 hit on glutathione S-transferase π and µ. The 1st MG132 hit significantly raises
glutathione S-transferase µ such that it is upregulated at the time of the 2 nd MG132 hit
(Fig 14J). However, no significant increase in glutathione S-transferase π with the 1st
MG132 hit was observed (Fig 15B). In summary, glutamate cysteine ligase modifier
subunit and glutathione S-transferase µ may promote glutathione defenses in our model.

63

Figure 14. See below for figure legend
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Figure 14. Inhibition of glutathione synthesis but not Hsp70/Hsc70 activity abolishes stress-induced
protection against the 2nd MG132 hit. A) Cortical astrocytes were treated with the indicated
concentrations of MG132 in the absence or presence of the Hsp70/Hsc70 inhibitor VER155008 and
glutathione synthesis inhibitor buthionine sulfoximine (BSO). Viable Hoechst+ nuclei were quantified
24h after the 2nd hit to measure viability. B) Data from panel A were expressed as a percentage of the 0
M 2nd MG132 hit groups (i.e. all gray bars were expressed as a percentage of the adjacent black bars).
C) Representative images of Hoechst-stained nuclei from data shown in panel A. D) Total glutathione
levels were measured 24h after the 2nd MG132 hit by the In-Cell Western technique and expressed as a
function of the corresponding number of Hoechst+ nuclei to control for differences in cell density. E)
Representative image of total glutathione In-Cell Western. F-H) Reduced glutathione levels were
measured intracellularly and in the extracellular media by the Glutathione-Glo assay and luminescence
was expressed as a function of the number of Hoechst+ nuclei on parallel plates. All glutathione assays in
F-H were performed 24h after the final MG132 hit. I-J) Western blot analysis of glutamate cysteine
ligase modifier subunit (GCLM) and glutathione S-transferase µ (GST-µ) in lysates collected 24h after
the 1st MG132 hit. K) Astrocytes were treated with single and dual hits of MG132 in the absence or
presence of BSO and ATP levels were measured by the CellTiter-Glo assay 24h after the 2nd MG132 hit.
ATP levels are expressed as a function of Hoechst+ cell numbers on parallel plates. * p ≤ 0.05, ** p ≤
0.01, *** p ≤ 0.001 vs 0 M 2nd MG132 hit; + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 vs 0 M 1st MG132
hit; ^ p ≤ 0.05, ^^ p ≤ 0.01 vs 0 M VER155008 and/or 0 µM BSO, two- or three-way ANOVA followed
by Bonferroni post hoc correction. For F-G and I-J, the two-tailed paired Student’s t test was employed.
Reprinted from “Astrocytes surviving severe stress can still protect neighboring neurons from proteotoxic
stress,” by A. M. Gleixner, 2015, Molecular Neurobiology, Epub ahead of print. Copyright [2015] by
A.M Gleixner. Reprinted with permission.
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A

B

Figure 15. Impact of 1st hit on glutathione-related enzymes. Astrocytes were treated with
the 1st MG132 hit or vehicle and the following glutathione-related proteins were measured
in lysates collected 24h later: A) glutamate cysteine ligase catalytic subunit (GCLC), B)
glutathione S-transferase π (GST-π). No significant difference was determined with the twotailed paired Student’s t test. Reprinted from “Astrocytes surviving severe stress can still
protect neighboring neurons from proteotoxic stress,” by A. M. Gleixner, 2015, Molecular
Neurobiology, Epub ahead of print. Copyright [2015] by A.M Gleixner. Reprinted with
permission.
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Glutathione synthesis inhibition increases ATP levels in severely stressed astrocytes
ATP is important for fueling defensive responses in cells, and supplies energy for
glutathione synthesis and heat shock protein activity (Bukau & Horwich, 1998; S. C. Lu,
2009; Mayer & Bukau, 2005). Therefore, we measured ATP levels in our model. ATP
levels were increased in astrocytes treated with the 1st, 2nd, and dual MG132 hits (Fig
14K). The pattern in Figure 14K appears different from the pattern in Figure 3a in our
previous model because we expressed ATP as a function of cell numbers. The data were
expressed in this manner because Figure 3a does not take into consideration changes in
astrocyte numbers; ATP loss might therefore mean loss of cell numbers, a drop in ATP
output per cell, or both. BSO promoted a large increase in ATP levels in the dual hit
group. Despite this increase in ATP, previously stressed astrocytes were susceptible to
the 2nd MG132 hit in the presence of BSO, suggesting that the increase in ATP was not
sufficient for protecting astrocytes. On the other hand, it is also possible that in the
absence of the BSO-mediated rise in ATP, the stressed astrocytes would have been all the
more vulnerable to MG132.
System xc- may not mediate protection in severely stressed astrocytes
Cysteine availability is often the rate-limiting component of glutathione synthesis
and is determined partly by the system xc- glutamate/cysteine antiporter (Bannai &
Kitamura, 1980; Jackman, Melchior, Hewett, & Hewett, 2012; Sato et al., 2002). Thus,
we tested the hypothesis that system xc- would contribute to the stress-induced tolerance
in this model. However, LY367385, a system xc- and metabotropic glutamate receptor
inhibitor (mGluR1), did not attenuate the resistance of previously stressed astrocytes to
subsequent insults. To control for potential off-target effects of LY367385, YM298198, a
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specific mGluR1 inhibitor, was also used. YM298198 did not attenuate the tolerance of
previously stressed astrocytes towards subsequent MG132 insults, as expected (Fig 16A
& B). Therefore, system xc- may not contribute to glutathione-mediated protection of
stressed astrocytes against subsequent proteotoxic insults. Further studies are nevertheless
warranted, because of the possibility that both inhibitors only acted on mGluR1.
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Figure 16. System xc- is not essential for resilience in severely
stressed astrocytes. Cortical astrocytes were treated with the indicated
1st and 2nd MG132 hit in the absence and presence of pharmacological
inhibitors LY367385 and YM298198. A) Viability was assessed by
blinded cell counts of Hoechst+ nuclei. B) Representative images of
Hoechst-stained nuclei * p ≤ 0.05, ** p ≤ 0.01 vs 0 M 2nd MG132 hit,
++ p ≤ 0.01, vs 0 M 1st MG132 hit three-way ANOVA followed by
Bonferroni post hoc correction. Reprinted from “Astrocytes surviving
severe stress can still protect neighboring neurons from proteotoxic
stress,” by A. M. Gleixner, 2015, Molecular Neurobiology, Epub ahead
of print. Copyright [2015] by A.M Gleixner. Reprinted with permission.
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Heme oxygenase 1 activity is not essential for stress tolerance in astrocytes
As mentioned above, HO1 is a highly stress responsive protein that prevents cell
death in response to oxidative injury (Schipper, et al., 2009). Furthermore, oxidative
stress can be propagated by proteasome inhibition (Maharjan, Oku, Tsuda, Hoseki, &
Sakai, 2014). Thus, we hypothesized that HO1 also contributes to the stress-induced
tolerance in our model. As described above, the 1st MG132 hit elicited a trend towards an
increase in HO1 protein levels (see Fig 13E). A competitive inhibitor of HO1 activity, tin
protoporphyrin IX, did not alter the effect of MG132 on astrocytes in the dual hit model
(Fig 17A & B). Pilot data show that the inhibitor does reduce HO1 activity (data not
shown). Therefore, HO1 may not be responsible for the stress-induced protection in our
model, although further studies to verify the efficacy of the HO1 inhibitor are in order.
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Figure 17. Stressed astrocytes can resist dual hits despite HO1 inhibition. A) Astrocytes were
treated with the 1st and 2nd MG132 hits 24h apart in the absence or presence of the heme oxygenase
1 inhibitor SnPPx. Viability was assayed 24h after the 2 nd hit. B) Representative images of Hoechst
stained nuclei. * p ≤ 0.05, *** p ≤ 0.001 vs 0 M 2nd MG132 hit, + p ≤ 0.05, +++ p ≤ 0.001 vs 0 M
1st MG132 hit, two-way ANOVA followed by Bonferroni post hoc correction. Reprinted from
“Astrocytes surviving severe stress can still protect neighboring neurons from proteotoxic stress,”
by A. M. Gleixner, 2015, Molecular Neurobiology, Epub ahead of print. Copyright [2015] by A.M
Gleixner. Reprinted with permission.
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Severely stressed astrocytes can still blunt proteotoxic cell death in neurons, even in the
absence of glutathione and Hsp70/Hsc70 defenses
As shown above, glutathione synthesis is essential for protecting stressed
astrocytes from subsequent proteotoxic insults. Astrocytes are known to provide
glutathione precursors for neighboring neurons, which may prevent neuronal death
during stress exposure (Dringen, et al., 2000; Dringen, et al., 1999). Therefore, we
investigated whether severely stressed astrocytes can decrease proteotoxic stress in
neighboring neurons and whether glutathione synthesis is essential for this effect.
Neuron-astrocyte co-cultures were developed to answer this question and were conducted
in collaboration with Dr. Jessica Posimo. Astrocytes were stressed with a 1st MG132 hit
and the MG132 was then removed before neurons were plated in direct contact with the
glial cells. The neuron-astrocyte contact co-cultures were then administered a 2nd MG132
hit (2nd hit in reference to astrocytes). Neuron viability was measured by In-Cell Western
analysis for the neuronal marker MAP2 (Caceres, Banker, Steward, Binder, & Payne,
1984; Posimo, et al., 2014). Other studies have verified that the MAP2 In-Cell Western
assay is a sensitive measure of neuronal viability (Posimo, et al., 2014). Primary neurons
plated alone were highly susceptible to MG132 (Fig 18A & B). There was a trend
towards neuroprotection against MG132 in the presence of unstressed astrocytes
(p=0.067) (Fig 18A). In contrast, the severely stressed astrocytes attenuated neuronal
death in response to the 2nd MG132 hit in a statistically significant manner. Surprisingly,
inhibition of glutathione synthesis by BSO did not alter the effect of MG132 toxicity on
neurons or the protective effects of astrocytes on neuronal viability. In order to verify that
BSO was eliciting the expected decrease in glutathione, glutathione levels were measured
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in the neuron-astrocyte co-cultures. The results show that 1) the presence of astrocytes
significantly increased overall glutathione levels, 2) the 2nd MG132 hit significantly
increased glutathione levels in a concentration-dependent manner, and 3) BSO abolished
these effects (Fig 18C-E). These findings indicate that stressed co-cultures increase
glutathione synthesis. We conclude that glutathione is not essential for astrocytemediated protection of neurons from proteotoxicity although it is essential for protection
of previously stressed astrocytes from subsequent insults.
Finally, we measured GFAP levels in co-cultures treated with BSO and MG132,
as GFAP is a phenotypic marker of astrocytes. Some GFAP was detected in the neurononly group, because our primary neuronal cultures are derived from postnatal day 1-2 rat
pups (a time at which astrocyte births peak) and contain 9.5% astrocytic cells (F. D.
Miller & Gauthier, 2007). As expected, GFAP levels were dramatically higher in the coculture groups (Fig 18F & G). It is worth noting here that GFAP levels are not always in
proportion to the number of cells because GFAP is a reactive stress marker. Therefore,
we cannot use GFAP in an In-Cell Western analysis as a measure of astrocyte numbers.
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Figure 18. Severely stressed astrocytes
can protect neurons from proteotoxic
stress. A) Astrocytes were treated with
the 1st MG132 hit 24h prior to
introduction of neocortical neurons, in
the absence or presence of the
glutathione
synthesis
inhibitor
buthionine sulfoximine (BSO). Two
days after the introduction of neurons,
the neuron/astrocyte co-cultures were
treated with MG132 as a 2nd hit in the
absence or presence of BSO. Two days
after the 2nd hit, neuronal viability was
measured by the In-Cell Western assay
for the specific neuronal marker MAP2.
B) Representative image of MAP2 InCell Western. C) Changes in glutathione
levels were measured by In-Cell
Western analyses and expressed as a
function of the infrared nuclear stain
DRAQ5. Representative images of
glutathione immunostaining (D) and
DRAQ5 levels (E). F) The astrocytic
marker GFAP was measured by In-Cell
Western analysis in neuron/astrocyte cocultures 48h after the 2nd MG132 hit in
the absence or presence of BSO. G)
Representative image of GFAP In-Cell
Western. ** p ≤ 0.01, *** p ≤ 0.001 vs 0
M 2nd MG132 hit, + p ≤ 0.05, ++ p ≤
0.01, +++ p ≤ 0.001 vs neurons, ^ p ≤
0.05, ^^ p ≤ 0.01, ^^^ p ≤ 0.001 vs 0 M
BSO, three-way ANOVA followed by
Bonferroni
post
hoc
correction.
Reprinted from “Astrocytes surviving
severe
stress
can
still
protect
neighboring neurons from proteotoxic
stress,”
by
A.
M.
Gleixner,
2015, Molecular Neurobiology, Epub
ahead of print. Copyright [2015] by
A.M
Gleixner.
Reprinted
with
permission.
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Astrocytes robustly protect neurons against the synergistic toxicity of proteasome and
Hsp70 inhibition
Although stressed astrocytes do not rely on Hsp70 activity for protection against
subsequent proteotoxic insults, Hsp70 may be released from astrocytes via exosomes in
order to protect neighboring cells, such as neurons, from proteotoxicity (Lancaster &
Febbraio, 2005; Taylor, et al., 2007; Zhan et al., 2009). Therefore, we tested the
hypothesis that the Hsp70 inhibitor VER155008 would attenuate the neuroprotection
afforded by astrocytes. As before, MG132 significantly decreased neuron viability in the
neuron-only group. Furthermore, naïve and previously stressed astrocytes both attenuated
MG132 toxicity in neurons. Significant protection against MG132 toxicity in neurons by
naïve astrocytes may have been observed in these experiments and not the previous
experiments in Figure 18 because MG132 was less toxic in the later experiments. The
variability in MG132 toxicity may be attributed to differences in MG132 stock solutions
or the quality of the neuronal cultures. However, all the trends in the two sets of data are
identical and speak to the reproducibility of the neuroprotective properties of stressed
astrocytes. In the neuron-only group, Hsp70 inhibition by VER155008 and proteasome
inhibition by MG132 elicited a synergistic decrease in neuron viability (Fig 19A-C).
Naïve and previously stressed astrocytes significantly protected neurons against the
synergistic toxicity of MG132 and VER155008, an effect that is also evident when the
data are expressed as a percentage of the 0 µM VER155008 group (Figure 19B). As
observed in the earlier co-culture studies, GFAP levels were higher in the neuronastrocyte co-culture group, and some GFAP was detected in the neuron-only group (Fig
19D & E).
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Figure 19. Stressed astrocytes prevent the synergistic toxicity of proteasome and Hsp70/Hsc70
inhibitors. A) Astrocytes were treated with the 1st MG132 hit 24h prior to introduction of
neocortical neurons, in the absence or presence of the Hsp70/Hsc70 inhibitor VER155008. Two
days after the introduction of neurons, the neuron/astrocyte co-cultures were treated with MG132 as
a 2nd hit in the absence or presence of VER155008. Two days after the 2 nd hit, neuronal viability was
measured by the In-Cell Western assay for MAP2. B) Data from panel A were expressed as a
percentage of the 0 M VER155008 groups to illustrate the exacerbation of MG132 toxicity by
VER155008. C) Representative image of MAP2 In-Cell Western. D) The astrocytic marker glial
fibrillary acidic protein (GFAP) was analyzed by In-Cell Western analyses 48h after the 2nd hit in
the same neuron/glia co-cultures as shown in panels A-C. E) Representative image of GFAP In-Cell
Western. * p ≤ 0.05, *** p ≤ 0.001 vs 0 M 2nd MG132 hit, + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001
vs neurons, ^ p ≤ 0.05, ^^ p ≤ 0.01, ^^^ p ≤ 0.001 vs 0 M VER155008, three-way ANOVA
followed by Bonferroni post hoc correction. Reprinted from “Astrocytes surviving severe stress can
still protect neighboring neurons from proteotoxic stress,” by A. M. Gleixner, 2015, Molecular
Neurobiology, Epub ahead of print. Copyright [2015] by A.M Gleixner. Reprinted with permission.
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Astrocytes-mediated neuroprotection is dependent upon physical contacts
Astrocytes are known to support neurons by providing metabolic precursors,
antioxidants, and trophic factors (Allen & Barres, 2009). Thus, we sought to determine
whether astrocytes release a diffusible factor in order to protect neurons against
proteotoxicity using astrocyte-conditioned media (ACM). First, astrocytes were treated
with MG132 for 24h. The ACM was then added to neuron growth media (at a dilution of
1:1) in primary neuron cultures. Neurons with or without ACM were then treated with an
MG132 insult (2nd MG132 hit) and neuron viability was measured 24h later. As expected,
neuron viability was decreased by the 2nd MG132 hit, but conditioned media from either
stressed or unstressed astrocytes completely failed to alter the effect of MG132 on neuron
viability (Fig 20A & B). Because the diffusible factors may have been too dilute with our
protocol, ACM was also concentrated by centrifugation and delivered to neurons at a 10×
concentration. However, concentrated ACM also did not alter the effect of MG132 on
neuron viability either (data not shown).
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Figure 20. Stressed neurons are not protected from
proteotoxicity by astrocyte-conditioned media. A) The 1st
MG132 hit or an equivalent v/v of vehicle was added for 24h to
wells in the presence of astrocytes (conditioned media) or in
their absence (unconditioned media). Conditioned and
unconditioned media (still containing 1st hit MG132 or vehicle)
were then delivered to neocortical neurons by diluting them 1:1
in neuron media. The 2nd MG132 hit was administered at the
time of media transfer. Neuronal viability was measured by the
In-Cell Western assay for MAP2 48h after media transfer. B)
Representative image of MAP2 In-Cell Western. *** p ≤ 0.001
vs 0 M 2nd MG132 hit, three-way ANOVA followed by
Bonferroni post hoc correction Reprinted from “Astrocytes
surviving severe stress can still protect neighboring neurons
from proteotoxic stress,” by A. M. Gleixner, 2015, Molecular
Neurobiology, Epub ahead of print. Copyright [2015] by A.M
Gleixner. Reprinted with permission.
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3.2 N-acetyl cysteine-mediated protection of astrocytes against proteotoxicity is
dependent upon heat shock protein activity
N-acetyl cysteine attenuates proteotoxicity in astrocytes
N-acetyl cysteine (NAC) has shown beneficial effects in multiple neurological
conditions (Adair, et al., 2001; Berk, Copolov, Dean, Lu, Jeavons, Schapkaitz, AndersonHunt, Judd, et al., 2008; Berk, Copolov, Dean, Lu, Jeavons, Schapkaitz, Anderson-Hunt,
& Bush, 2008; M. E. Hoffer, et al., 2013). These therapeutic effects of NAC are thought
to be mediated by antioxidant effects on neurons. As astrocytes are known to support
neurons, it is also important to protect astrocytes from protein misfolding stress in
neurological conditions so that they can continue to promote neuronal health. Therefore,
we sought to determine the therapeutic potential of NAC in astrocytes exposed to
proteotoxicity. First, we hypothesized that NAC would prevent MG132 toxicity in
cortical astrocytes. Consistent with this expectation, NAC decreased the MG132-induced
loss of Hoechst+ nuclei in a concentration-dependent manner (Fig 21A). Representative
images of Hoechst-stained nuclei and the preservation of cellular morphology by NAC
are presented in Figure 21B and C.
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Figure 21. NAC protects astrocytes from MG132 toxicity. Cortical astrocytes were treated with
vehicle (DMSO) or a range of MG132 concentrations in the presence of 3 mM NAC or vehicle
(H2O, equivalent v/v). A) Viability was determined 48h later by blinded counts of Hoechst+ nuclei.
B) Representative images of Hoechst+ nuclei. C) Representative images of astrocytes stained for
S100β (green), glial fibrillary acidic protein (GFAP, red), and Hoechst (blue). Shown are the mean ±
SEM of 3 independent experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 versus 0 µM MG132; ++
p ≤ 0.01, +++ p ≤ 0.001 versus 0 mM NAC, two-way ANOVA followed by Bonferroni post hoc test.
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NAC protects astrocytes independent of glutathione synthesis
As mentioned above, proteotoxic stress is often associated with oxidative stress.
NAC is known to be a glutathione precursor and can also have direct antioxidant effects
(Aruoma, Halliwell, Hoey, & Butler, 1989; E. Hoffer, Baum, Tabak, & Taitelman, 1996).
Therefore, we sought to determine whether NAC protects astrocytes from MG132
toxicity through a glutathione-dependent mechanism. MG132 increased total glutathione
levels in a concentration-dependent manner and NAC unexpectedly attenuated this effect
(Fig 22A & B). These data suggest that NAC protects astrocytes in a glutathioneindependent manner. In order to test this directly, we used the glutathione synthesis
inhibitor BSO to decrease glutathione levels (Fig 22C &D). As outlined above, the InCell Western assay measures total glutathione levels, which include both the reduced and
oxidized forms. The reduced form of glutathione is important for defense against
oxidative stress. Thus, reduced glutathione levels were also measured in our model.
MG132 significantly increased intracellular levels of reduced glutathione, and NAC
attenuated the rise in glutathione in response to MG132, consistent with the
abovementioned results of the In-Cell Western assay. Reduced glutathione levels were
slightly increased in the presence of NAC in cells not exposed to MG132 (Fig 22E). No
significant changes in reduced glutathione levels were observed in the extracellular space
with the exception of a BSO-induced decrease in reduced glutathione in the NAC-treated
group (Fig 22F). These results suggest that MG132 elicits a stress-induced increase in
glutathione synthesis but that there may be less need for this compensatory stress
response in the presence of NAC.
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Next, we tested whether glutathione synthesis is essential for NAC-mediated
protection against MG132 toxicity in astrocytes. Glutathione synthesis was inhibited by
BSO and astrocyte viability was measured by counting the number of Hoechst +
astrocytes. BSO did not abolish or even attenuate the protective effects of NAC (Fig 22G
& H). These findings suggest that glutathione synthesis is not essential for NACmediated protection against MG132 toxicity.
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Figure 22. NAC protects astrocytes against MG132 independent of glutathione synthesis.
Cortical astrocytes were treated with the indicated MG132 concentrations in the presence of NAC
(3 mM) or the equivalent v/v of vehicle. A) Total glutathione levels were measured 48h later by
the fluorescent In-Cell Western assay. Total glutathione levels are expressed as a function of the
number of Hoechst+ cell numbers. B) Representative total glutathione In-Cell Western image for
data presented in panel A. C) Total glutathione levels as a function of the number of Hoechst +
nuclei in the absence and presence of glutathione synthesis inhibitor, buthionine sulfoximine
(BSO). D) Representative In-Cell Western image of total glutathione levels for data presented in
panel C. Intracellular (E) and extracellular (F) reduced glutathione levels in the absence or
presence of BSO were measured by the luminescent GSH-Glo assay. G) Blinded counts of the
number of Hoechst+ nuclei in the absence or presence of BSO. H) Representative images of
Hoechst+ nuclei for the data shown in panel G. Shown are the mean and SEM of 3-5 independent
experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 versus 0 µM MG132; + p ≤ 0.05, ++ p ≤ 0.01,
+++ p ≤ 0.01 versus 0 mM NAC; ^ p ≤ 0.05, ^^ p ≤ 0.01, ^^^ p ≤ 0.001 versus 0 µM BSO, twoor three-way ANOVA followed by Bonferroni post hoc correction.
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Cysteine thiols protect astrocytes against protein-misfolding stress
We had shown in Figure 22 that NAC did not protect against MG132 toxicity by
increasing glutathione levels. In order to elucidate the mechanism underlying NACmediated glioprotection, the therapeutic potential of two cysteine isoforms was tested.
Cysteine can exist in the L- or D- conformation, with L-cysteine being the biologically
active form of cysteine that can be incorporated into glutathione whereas D-cysteine
cannot be directly incorporated into glutathione (Corcoran & Wong, 1986). Both forms of
cysteine contain a thiol group, which is known to attenuate oxidative stress (Requejo,
Hurd, Costa, & Murphy, 2010). Figure 23 illustrates that both D- and L-cysteine
(subpanels A & B and C & D, respectively) protect astrocytes against MG132 toxicity.
D-amino acids may be converted to L-amino acids by D-amino acid oxidase
(Friedman & Levin, 2012; Sacchi, et al., 2008). Therefore, in order test whether Dcysteine was protective due to conversion to L-cysteine, D-amino acid oxidase was
inhibited with sodium benzoate (Gong et al., 2011; Van den Berghe-Snorek &
Stankovich, 1985). Sodium benzoate did not affect the protection against MG132 toxicity
by D- and L-cysteine (Fig 23E-H). Therefore, we speculate that protection against
MG132 toxicity by all three cysteines (NAC, L-cysteine, and D-cysteine) may occur
through the thiol that they all have in common.
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Figure 23. D-cysteine and L-cysteine protect astrocytes against MG132 toxicity. Cortical
astrocytes were treated with MG132 or vehicle in the presence of D-cysteine (A, B) and Lcysteine (C, D) or vehicle. (E-H) Sodium benzoate was delivered in conjunction with D- and Lcysteine to inhibit the conversion of D- to L-cysteine by D-amino acid oxidase. Viability was
measured 48h later by blinded counts of the number of Hoechst + nuclei. Representative images of
Hoechst+ nuclei are illustrated. Shown are the mean and SEM of 3-6 independent experiments. **
p ≤ 0.01, *** p ≤ 0.001 versus 0 µM MG132; + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 vs 0 mM Dcysteine or L-cysteine, two- or three-way ANOVA followed by Bonferroni post hoc test.
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NAC attenuates the stress-induced upregulation of several heat shock proteins
We previously showed that NAC protects neuroblastoma cells in a heat shock
protein-dependent manner (Jiang, et al., 2013). Thus, here we examined heat shock
proteins in MG132- and NAC-treated astrocytes. Proteotoxic stress elicited a significant
increase in multiple heat shock proteins but NAC attenuated this effect, in contrast with
the findings in neuroblastoma cells (Fig 24). Although NAC attenuated the rise in Hsp70
and HO1 under proteotoxic conditions, these heat shock proteins remain elevated relative
to the 0 µM MG132 group in the presence of NAC (Fig 24A & C, respectively). Thus,
these heat shock proteins may nevertheless contribute to the protective effects of NAC.
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Figure 24. NAC attenuates the MG132-induced increase in heat shock proteins in astrocytes.
Cortical astrocytes were treated with MG132 or vehicle in the presence or absence of NAC. Lysates
were collected 24h later and heat shock proteins were measured by Western blot analysis.
Representative Western blot images are included below each graph. A) Heat shock protein 70
(Hsp70), B) heat shock cognate 70 (Hsc70), C) heme oxygenase 1 (HO1 or heat shock protein 32), D)
heat shock protein 25 (Hsp25), E & F) phosphorylated Hsp25, G) heat shock protein 40 (Hsp40), and
H) heat shock protein 90 (Hsp90). Protein levels are expressed as a function of the loading controls βactin, GAPDH or α-tubulin, depending upon the species of the antibody for the protein of interest and
its MW. Shown are the mean and SEM of 3-5 independent experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p
≤ 0.001 versus 0 µM MG132; + p ≤ 0.05, +++ p ≤ 0.01 versus 0 mM NAC, two-way ANOVA
followed by Bonferroni post hoc test.
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Hsp70 and HO1 activity are essential for NAC-mediated protection of astrocytes against
proteotoxicity
As mentioned above, Hsp70 is important for defending against proteotoxicity and
is increased in response to proteasome inhibition by MG132. Geldanamycin is an Hsp90
inhibitor and is known to increase Hsp70 levels as a result of Hsp90 inhibition (McLean,
Klucken, Shin, & Hyman, 2004; Shen, He, Wang, Huang, & Chen, 2005). Thus we tested
the hypothesis that geldanamycin protects astrocytes against MG132 toxicity as proof of
principle. As expected, we found that geldanamycin abolished MG132 toxicity in
astrocytes (Fig 25A & B).
In Figure 24, we had shown that NAC attenuated the MG132-induced rise in
Hsp70. However, Hsp70 levels were still significantly higher in the MG132-treated group
in the presence of NAC relative to cells not exposed to MG132, suggesting that Hsp70
may still contribute to the protective effects of NAC. Therefore, we next tested the
hypothesis that Hsp70 inhibitors would abolish the protective effects of NAC. Consistent
with this hypothesis, the protective effects of NAC were attenuated by three independent
Hsp70 pharmacological inhibitors with unique mechanisms of action: VER155008 (Fig
26A-C), pifithrin-µ (Fig 26D-F), and MAL3-101 (Fig 26G & H). These findings strongly
suggest that Hsp70 activity may be an important factor in the protective effects of NAC.
Inhibition of Hsp70 by itself did not increase the susceptibility of astrocytes to MG132 in
the absence of NAC. Therefore, it is possible that other heat shock proteins compensate
for Hsp70 inhibition in this group and prevent any additional decrease in viability with
MG132.
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We previously observed that NAC elicited a trend towards an increase in HO1 in
MG132-treated neuroblastoma cells (Jiang, et al., 2013). Thus, here we tested the
hypothesis that inhibition of HO1 would also attenuate NAC-mediated protection.
Consistent with this hypothesis, inhibition of HO1 activity by SnPPx attenuated the
protective effects of NAC in astrocytes (Fig 27A & B). Therefore, heat shock protein
activity (Hsp32 or HO1 and Hsp70) appears to contribute to the NAC-mediated
protection against MG132 toxicity (Fig 26 & 27).
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Figure 25. Geldanamycin protects against MG132 toxicity in astrocytes Cortical astrocytes were
treated with 0.2 µM MG132 and geldanamycin (312.5, 625, 1250 pM). A) Astrocyte viability was
determined by blinded counts of Hoechst+ nuclei B) Representative image of Hoechst-stained nuclei. **
p ≤ 0.01, *** p ≤ 0.001 versus 0 µM MG132; ~ p ≤ 0.05vs 0 pM geldanamycin two-way ANOVA
followed by Bonferroni post hoc test.
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Figure 26. Loss of Hsp70/Hsc70 activity abolishes NAC-mediated protection in astrocytes.
Cortical astrocytes were treated with MG132 or vehicle in the presence or absence of NAC and the
Hsp70/Hsc70 inhibitors VER155008 (A-C), pifithrin-µ or PES (D-F), and MAL3-101 (G-H). Cell
viability was measured by blinded counts of Hoechst-stained nuclei. VER155008 and pifithrin-µ
led to loss of basal viability. Thus, data in panels A and D were expressed as a percentage of the 0
µM MG132 group in panels B and E to account for the basal viability loss. Representative images
of Hoechst+ nuclei are illustrated in C, F, and H. Shown are the mean and SEM of 3-5 independent
experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 versus 0 µM MG132; + p ≤ 0.05, ++ p ≤ 0.01,
+++ p ≤ 0.001 versus 0 mM NAC; ^ p ≤ 0.05, ^^ p ≤ 0.01, ^^^ p ≤ 0.001 versus 0 µM VER155008,
pifithrin-µ, or MAL3-101, three-way ANOVA followed by Bonferroni post hoc correction.
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Figure 27. Inhibition of HO1 activity attenuates protective effects of NAC Cortical astrocytes
were treated with the indicated concentration of MG132 in the absence and presence of NAC and
HO1 inhibitor tin protoporphoryrin (SnPPx). A) The relative number of viable astrocytes was
determined by blinded counts of Hoechst+ nuclei. B) Representative images of Hoechst-stained
nuclei. *** p ≤ 0.001 versus 0 µM MG132; +++ p ≤ 0.001 versus 0 mM NAC; ^^^ p ≤ 0.001 versus
0 µM SnPPx three-way ANOVA followed by Bonferroni post hoc correction.
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NAC attenuates protein-misfolding stress after MG132 treatment
As NAC reduced the toxicity of MG132, we tested the hypothesis that it would
also reduce the increase in ubiquitinated proteins normally seen with proteasome
inhibitors. Consistent with this hypothesis, NAC abolished the dramatic rise in
ubiquitinated proteins in response to MG132 treatment, suggesting that proteotoxicity
was robustly attenuated by NAC (Fig 28A). Previous studies by our group have shown
that NAC does not reverse MG132-mediated inhibition of proteasome activity in
neuroblastoma cells (Jiang, et al., 2013). Those studies suggest that NAC does not reduce
the extent of the original insult, but protects cells downstream from the proteasome.
Consistent with this notion, NAC did not alter the levels of the proteasomal subunits
PA28α and PA700 (42 & 46 kDa subunits) in our model (Fig 25B-D). These findings
support the view that the protective effects of NAC are not related to direct alterations in
the ubiquitin proteasome system but help mitigate the downstream toxic effects of the
proteasome inhibtors.
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Figure 28. NAC decreases ubiquitinated
proteins in astrocytes after MG132
treatment. Cortical astrocytes were treated
with MG132 or vehicle. Lysates were
collected 24h later and Western blots were
performed. Representative images are
shown adjacent to the quantification. A)
Ubiquitinated proteins, B) PA28α, C)
PA700 42 kDa subunit, and D) PA700 46
kDa subunit. All proteins are expressed as a
fraction of β-actin or α-tubulin levels.
Infrared images were pseudocolored green
and red. Shown are the mean and SEM of 3
independent experiments. * p ≤ 0.05, *** p
≤ 0.001 versus 0 µM MG132; +++ p ≤
0.001 versus 0 mM NAC, two-way
ANOVA followed by Bonferroni post hoc
test.
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3.3 Impact of aging on heat shock proteins in the female rat
Aging is the best known risk factor for the development of neurodegenerative
diseases (Lindsay et al., 2002; Van Den Eeden, et al., 2003). Protein misfolding and
oxidative stress are thought to accumulate with advancing age (Alavez, Vantipalli,
Zucker, Klang, & Lithgow, 2011; Attems, Walker, & Jellinger, 2014; Cuanalo-Contreras,
Mukherjee, & Soto, 2013; David et al., 2010; Driver, Kodavanti, & Mundy, 2000;
Mecocci et al., 1993; Muller, Lustgarten, Jang, Richardson, & Van Remmen, 2007).
Therefore, aging may contribute to the pathology associated with neurodegeneration.
Some heat shock protein defenses are upregulated in neurodegenerative diseases
(Schipper, et al., 2006; Schipper, et al., 1998; Uryu et al., 2006; Y. Zhang, James,
Middleton, & Davis, 2005). The effect of aging on several heat shock proteins has mostly
been measured in male animals (V. Calabrese, et al., 2004; Gupte, et al., 2010; Unno, et
al., 2000). However, women have a higher incidence of Alzheimer’s disease than men
(Fratiglioni, et al., 1997) and a lower incidence of Parkinson’s disease (Van Den Eeden,
et al., 2003), suggesting that there are sex-related differences in vulnerability to
proteotoxicity. Therefore, an examination of heat shock protein changes in aging females
is warranted. In the following studies, we used female animals for an extensive
examination of various heat shock proteins as a function of age, including those heat
shock proteins highly expressed in astrocytes. Heat shock proteins were examined in
brain regions known to exhibit pathology in neurodegenerative diseases, such as the
substantia nigra, striatum and olfactory bulb. We hypothesized that age-related stress
would be associated with an increase in heat shock proteins, based on previous work in
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other brain regions (V. Calabrese, et al., 2004; Di Domenico et al., 2010; Dickey, et al.,
2009; Schipper, et al., 2006).
Aging elicits distinct patterns of heat shock protein changes that vary depending upon
protein type and brain region
A significant increase in Hsp25 was observed in both the striatum and substantia
nigra from young to old age (Fig 29a and 30a). For example, the oldest animals (19-22
mo) showed significantly higher Hsp25 levels in the striatum than the youngest animals
(2-4 mo). Similarly, 19-22 mo old animals expressed higher Hsp25 levels in the
substantia nigra than 2-4 mo old animals as well as 4-6 mo old animals. Hsp25 levels
were also higher in the substantia nigra in 19-22 and 16-19 mo old animals than 8-9 mo
old animals. Hsp25 was elevated in the olfactory bulb after 4 months of age relative to
the 2-4 month old animals (Fig 32A).
Next we measured Hsp60 and Hsp70 levels as a function of age. In the striatum,
19-22 mo old animals expressed higher Hsp60 protein levels than 2-4, 8-9, and 16-19 mo
old animals (Fig 29e). Middle (8-9 mo) and old (19-22 mo) animals exhibited higher
Hsp70 levels in the olfactory bulb compared to the youngest animals (2-4 mo) (Fig 32C).
These findings support the hypothesis that age-related stress increases some heat shock
protein defenses in a compensatory fashion.
Proteins tagged specifically for proteasome degradation contain ubiquitin that is
linked through lysine 48 (K48-linked ubiquitin) (Sadowski & Sarcevic, 2010). In the
striatum, K48-linked ubiquitin was increased from 4-6 mo of age to 16-19 mo of age (Fig
29j). These findings are consistent with the view that there is an age-related decline in the
efficiency of the ubiquitin proteasome system.
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In our model, some heat shock proteins exhibited a biphasic response to aging, in
that there was a rise in heat shock proteins that was reversed with increasing age. For
example, in the striatum, HO1 protein levels were higher in 8-9 mo old animals relative
to 2-4 mo old animals (Fig 29b). However, HO1 levels were then decreased in the 16-19
and 19-22 mo old animals. A biphasic effect was also observed in Hsp60 levels in the
substantia nigra (Fig 30e) and Hsp40 levels in the striatum (Fig 29c). Middle-aged (8-9
mo) animals preserved GRP78 expression, whereas 4-6 and 16-22 mo old animals
exhibited lower GRP78 levels. The increase in heat shock protein defenses in middleaged animals may reverse early signs of proteotoxicity but these responses appear to fail
in the oldest groups.
Some heat shock protein defenses were also observed to decrease with advancing
age. For example, Hsc70 was decreased in old age in the striatum and olfactory bulb (Fig
29f and 32D). Further, HO1 protein levels were decreased from 2-4 to 16-19 months of
age in the substantia nigra (Fig 30b). The co-chaperone Hip was lower in 4-6 and 19-22
month old animals relative to young 2-4 month old animals (Fig 29d). The decrease in
Hip observed in 4-6 month old animals may be related to developmental changes whereas
lower Hip levels in the oldest animals may be suggestive of age-related declines in some
co-chaperone defenses.
Some heat shock proteins were not affected by aging in the striatum, substantia
nigra, and olfactory bulb. For example, striatal levels of GRP78, pan-ubiquitinated
proteins, and Hsp90 remained unaffected (Figure 29). No significant changes in GRP78,
pan-ubiquitinated proteins, Hsp90, Hsp40, Hip, Hsc70, and K48-linked ubiquitin were
observed in the substantia nigra (Figure 30). Furthermore, CHIP, HO1, Hsp90, Hip, Hop,
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Hsp60, and mitochondrial Hsp70 (mtHsp70) were not significantly altered by aging in
the olfactory bulb (Fig 33), Therefore, several heat shock proteins are not upregulated
with aging and may require higher levels of proteotoxic stress before a response is
elicited.
As Hsp25 was shown to be higher with aging in both the substantia nigra and
striatum, we suspected that Hsp25 may be present in the dopaminergic neurons that
comprise the nigrostriatal pathway. As expected, a confocal analysis revealed that Hsp25
colocalized with tyrosine hydroxylase staining in young, female rats (Fig 31a-c).
Tyrosine hydroxylase is the rate limiting enzyme for dopamine synthesis and can be used
as a marker for dopaminergic nigral neurons (Pickel, Joh, Field, Becker, & Reis, 1975).
Our findings therefore, suggest that Hsp25 is expressed in dopaminergic neurons. Not
surprisingly, Hsp25 was also expressed in cells lacking tyrosine hydroxylase staining, as
this protein is known to be ubiquitous and expressed heavily in glia. Age-related
increases in Hsp25 in the midbrain may help mitigate age-related proteotoxicity in
dopaminergic neurons as well as other cell types such as astrocytes. Other heat shock
proteins (HO1 and Hsp60) were also examined using dual-immunofluorescence.
However, levels of HO1 and Hsp60 in the substantia nigra were below the limits of
immunohistochemical detection. In order avoid false positive conclusions from antibody
cross-reactivity, multiple control experiments were conducted. First, tissue sections were
incubated with one primary antibody (Hsp25 or tyrosine hydroxylase) only, followed by
exposure to both secondary antibodies. For example, Figure 31d-f illustrates nigral
staining with mouse antibodies raised against tyrosine hydroxylase antibodies followed
by exposure to secondary antibodies raised against both mouse and rabbit IgG molecules.
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The lack of staining in the red channel shows that the anti-rabbit secondary antibodies are
not cross-reacting inappropriately with the mouse primary antibodies, as we have on
occasion observed for various secondary antibodies. The lack of signal in the red channel
also shows clearly that the green tyrosine hydroxylase signal is not bleeding through to
the red channel during the microscopy. Second, we also ensured that signal was lost when
the tissue was incubated in no primary antibodies followed by both secondary antibodies.
In summary, some heat shock proteins were increased with aging in female
animals as was originally hypothesized. However, reductions and biphasic changes in
heat shock protein changes were also observed. The changes were highly dependent upon
the brain region examined, which is not surprising given the heterogeneity of the central
nervous system

99

Figure 29. Impact of aging on heat shock proteins and ubiquitinconjugated proteins in the striatum (caudoputamen). Whole tissue lysates
of striatal tissue from female Sprague-Dawley rats were probed by Western
blots for the indicated proteins. GAPDH, α-tubulin, or β-actin was used as a
protein loading control. * p  0.05 versus 2-4 month old, + p  0.05 versus 4-6
month old, ~ p  0.05 versus 8-9 month old, ^ p  0.05 versus 16-19 month
old. Reprinted from “Impact of aging on heat shock protein expression in the
substantia nigra and striatum of the female rat,” by A. M. Gleixner, 2014, Cell
Tissue Research, 357, 43-54. Copyright [2014] by A.M Gleixner. Reprinted
with permission.
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Figure 30. Impact of aging on heat shock proteins and ubiquitin-conjugated
proteins in the substantia nigra. Whole tissue lysates of substantia nigra tissue
from female Sprague-Dawley rats were probed by Western blots for the indicated
proteins. GAPDH, α-tubulin, or β-actin was used as a protein loading control. * p 
0.05 versus 2-4 month old, + p  0.05 versus 4-6 month old, ~ p  0.05 versus 8-9
month old, ^ p  0.05 versus 16-19 month old. Reprinted from “Impact of aging on
heat shock protein expression in the substantia nigra and striatum of the female rat,”
by A. M. Gleixner, 2014, Cell Tissue Research, 357, 43-54. Copyright [2014] by
A.M Gleixner. Reprinted with permission.
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Figure 31. Hsp25 expression in the substantia nigra. Confocal analysis of Hsp25 (red) and
TH (green) immunostaining in the substantia nigra, pars compacta of a young female rat (top
panels). Examples of dual-labeled neurons are indicated by white arrows. The dual-labeled
neurons do not appear yellow in the merged image on the right because the Hsp25 signal was
weak and the images are not overly manipulated. The bottom panels show an adjacent
midbrain section that was only incubated in primary antibodies against TH, followed by
exposure to the same secondary antibody solutions as in the top panels. Reprinted from
“Impact of aging on heat shock protein expression in the substantia nigra and striatum of the
female rat,” by A. M. Gleixner, 2014, Cell Tissue Research, 357, 43-54. Copyright [2014] by
A.M Gleixner. Reprinted with permission.
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Figure 32. Impact of aging on Hsps and co-chaperones in the olfactory bulb of the female
rat. (A-E) Infrared Western immunoblots are shown for the indicated Hsps and co-chaperones.
Olfactory bulb tissue was harvested from female rats at 2.0-3.9 months, 4.0-6.0 months, 8.0-9.0
months, 16.0-18.9 months, and 19.0-22.0 months of age. GAPDH, α-tubulin, or β-actin was used
as a protein loading control, depending on the species of the primary antibodies and the expected
molecular weights. n = 3-6 rats per group. * p ≤ 0.05, ** p ≤ 0.01, versus 2-4 month old, + p ≤
0.05, ++ p ≤ 0.01 versus 4-6 month old, ~ p ≤ 0.05, ~~ p ≤ 0.01 versus 8-9 month old, LSD post
hoc following one-way ANOVA. Reprinted from “Heat shock protein responses to aging and
proteotoxicity in the olfactory bulb,” by T.S. Crum, 2014, Journal of Neurochemistry, 133, 780794. Copyright [2014] by T.S.Crum. Reprinted with permission.
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Figure 33. Impact of aging on Hsps and co-chaperones in the olfactory bulb of the
female rat. (A-G) Infrared Western immunoblots are shown for the indicated Hsps and
co-chaperones. Olfactory bulb tissue was harvested from female rats at 2.0-3.9 months,
4.0-6.0 months, 8.0-9.0 months, 16.0-18.9 months, and 19.0-22.0 months of age. GAPDH,
α-tubulin, or β-actin was used as a protein loading control, depending on the species of the
primary antibody and the expected molecular weight. n = 3-6 rats per group. * p ≤ 0.05, **
p ≤ 0.01, versus 2-4 month old, + p ≤ 0.05, ++ p ≤ 0.01 versus 4-6 month old, ~ p ≤ 0.05,
~~ p ≤ 0.01 versus 8-9 month old, LSD post hoc following one-way ANOVA.
Reprinted from “Heat shock protein responses to aging and proteotoxicity in the olfactory
bulb,” by T.S. Crum, 2014, Journal of Neurochemistry, 133, 780-794. Copyright [2014]
by T.S.Crum. Reprinted with permission.
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Chapter 4 Discussion
4.1 Exposure to severe proteotoxic stress elicits tolerance in surviving astrocytes
Protein misfolding stress, or proteotoxicity, is known to affect both neurons and
glia in many neurodegenerative disorders, as evidenced by the appearance of protein
aggregates in both cell types (Braak et al., 2003; Braak, et al., 2007). Further evidence of
proteotoxicity in these conditions lies in the loss of protein quality control systems, such
as inhibition of proteasome activity (Cook & Petrucelli, 2009; Q. Huang & FigueiredoPereira, 2010). However, the impact of proteotoxicity on glial cells is less well defined
than on neurons. Astrocytes are known to harbor misfolded proteins in both Parkinson’s
and Alzheimer’s disease and to exhibit signs of activation without loss of cell numbers
(Korolainen, Auriola, Nyman, Alafuzoff, & Pirttila, 2005; Mythri, et al., 2011; Panter,
McSwigan, Sheppard, Emory, & Frey, 1985; Schultz, Hubbard, Rub, Braak, & Braak,
2000). These observations suggest that astrocytes are less vulnerable to proteotoxicity in
these conditions than neurons. If stressed astrocytes can continue to protect and support
neurons, the onset and progression of neurodegenerative disorders may be delayed.
Indeed, the slow and protracted nature of these conditions may be explained by both
neuronal and glial defense mechanisms that are activated by proteotoxic stress, such as
those examined in the present series of investigations.
It is well established that astrocytes can adapt to subtoxic levels of cellular stress,
a phenomenon known as preconditioning or tolerance (Pang, et al., 2015; Sen, et al.,
2011). For example, many studies have examined astrocytic adaptions to cellular stress at
levels that do not elicit any cell death (Chu, Beart, & Jones, 2010; Gao et al., 2014;
Rajapakse, Kis, Horiguchi, Snipes, & Busija, 2003). Even though astrocytes are known
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for their ability to adapt to a subtoxic, fluctuating environment, astrocytic adaptations to
severe cellular stressors are less well understood (Shao & McCarthy, 1994). Therefore,
we examined astrocytic responses to severe stress, or stress that is lethal to some fraction
of the cellular population under study. We tested the hypothesis that exposure to severe
proteotoxicity would render astrocytes less susceptible to subsequent insults. Although
astrocytes are not reduced in numbers in neurodegenerative disorders, it was essential to
significantly decrease astrocyte viability in our studies in order to answer this question.
We therefore applied lethal concentrations of proteasome inhibitors such as MG132 and
lactacystin and discovered that cells that managed to survive the first toxic exposure
exhibited no additional cell death in response to the second exposure to the same toxin.
These findings demonstrate that severely stressed astrocytes are not necessarily
weakened. On the contrary, those that survive are more resistant than naïve cells to toxic
challenges. This is the first study to reveal that astrocytes can adapt to proteotoxic stress
at concentrations that are high enough to kill a significant population of cells. In contrast
to these adaptive glial responses, many studies have shown that neurons are weakened by
exposure to high levels of stress, a phenomenon referred to as the dual hit hypothesis of
neurodegeneration (Boger, et al., 2010; Sulzer, 2007; Unnithan, et al., 2012; Zhu, et al.,
2007).
Next we sought to determine the mechanism underlying the protective effects of
severe stress in astrocytes. For these studies we focused on heat shock proteins and
glutathione, because heat shock proteins are elevated in astrocytes in Parkinson’s disease
while glutathione defenses are increased in resistant brain regions such as the frontal
cortex in this condition (Braak, Del Tredici, Sandmann-Kiel, Rub, & Schultz, 2001;
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Mythri, et al., 2011; Schipper, et al., 1998). Therefore, we hypothesized that the first hit
would upregulate heat shock protein and glutathione defenses. As expected, severely
stressed astrocytes exhibited higher levels of glutathione defenses and several heat shock
proteins 24h after the first hit (Fig 13 and 14). Similarly, both types of molecules were
upregulated 24h after the second hit. In order to test whether heat shock protein and
glutathione defenses mediated the protective effects induced by severe stress, we used the
pharmacological inhibitors VER155008, SnPPx, and BSO to inhibit Hsp70, Hsp32
(HO1), and glutathione, respectively. We observed that inhibition of glutathione but not
Hsp70 or HO1 completely abolished astrocyte stress tolerance (Fig 14 and 17). These
findings are consistent with the observation that astrocytes are one of the major sources
of glutathione in the brain (Makar, et al., 1994; Slivka, et al., 1987) and that glutathione
levels are upregulated in stressed astrocytes in neurodegenerative conditions (Mythri, et
al., 2011). Although one study demonstrated that heat shock protein 70 can increase
glutathione redox cycling (Guo, et al., 2007), we did not gather evidence that loss of
Hsp70 activity altered the ability of stressed astrocytes to resist subsequent proteotoxic
insults or that it negatively affected glutathione defenses (Fig 14). Instead, there was a
dramatic increase in glutathione levels in astrocytes treated with VER155008, which may
help explain why this compound failed to abolish stress resistance in this model. It
remains possible that the activity of Hsp70 and HO1 was insufficiently blocked, although
the reduction in basal survival with the inhibitors does not support this view. We were
unable to verify the efficacy of VER155008, as the assays for Hsp70 ATPase activity are
only specific when using pure recombinant Hsp70 and not when examining cellular
lysates containing multiple types of ATPases other than Hsp70. HO1 activity can be
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measured in cellular samples because of its unique conversion of toxic heme to bilirubin
(Drummond & Kappas, 1981; Yoshinaga, et al., 1982). Preliminary data showed that the
HO1 inhibitor SnPPx decreased enzymatic activity as expected. Another possibility for
the negative findings with Hsp70 and HO1 inhibitors is compensatory upregulation of
other heat shock proteins. For example, preliminary data in our lab has shown that Hsp90
and HO1 levels are elevated in the presence of VER155008.
As mentioned earlier, glutathione levels are preserved in astrocytes in brain
regions highly susceptible to Parkinson’s disease (Damier, et al., 1993; Mythri, et al.,
2011). Furthermore, patients with the disease exhibit higher glutathione levels in resilient
brain regions in comparison to control individuals. Similarly, we observed a stressinduced increase in glutathione levels that contributed significantly to astrocyte
resistance. Elimination of xenobiotics by glutathione in the presence of glutathione Stransferase may also contribute to astrocyte stress tolerance. As mentioned above,
glutathione S-transferases are enzymes that vary by their N-terminal domain amino acid
sequence (Mazzetti, et al., 2015). Both glutathione S-transferase μ and π are expressed in
astrocytes. The 1st MG132 hit increased glutathione S-transferase μ but not glutathione Stransferase π levels in astrocytes (Fig 14). The absence of glutathione S-transferase μ is
associated with an earlier age of onset of Parkinson’s disease (Ahmadi et al., 2000).
Furthermore, glutathione S-transferase μ null genotypes have been associated with a
higher incidence of Alzheimer’s disease (Piacentini et al., 2012). We also observed a
stress-induced increase in glutamate cysteine ligase, which plays a role in glutathione
synthesis. Taken together, these findings suggest that glutathione defenses are essential
for the protection of astrocytes from severe proteotoxic stress and that the absence of
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glutathione defenses may increase the likelihood of developing neurodegenerative
diseases.
In the present study, we measured viability by performing blinded cell counts of
Hoechst-stained nuclei and measuring ATP levels. ATP levels are not always in
proportion to cell numbers and are therefore only interpreted as an indicator of metabolic
fitness (Posimo, et al., 2014; Titler, et al., 2013). We were unable to use In-Cell Western
assays for the astrocytic marker GFAP as a third viability assay, because stressed
astrocytes are known to upregulate GFAP expression (Posimo, et al., 2014; Titler, et al.,
2013). One potential caveat of relying on the Hoechst assay is that it stains all nuclei
present, including those undergoing apoptosis. The Hoechst-positive nuclei of cells
undergoing apoptosis are often condensed, fragmented, and/or brightly stained (Abdel
Wahab, Abdul, Alzubairi, Mohamed Elhassan, & Mohan, 2009; Syed Abdul Rahman,
Abdul Wahab, & Abd Malek, 2013). Therefore, cells with nuclei under 50 µm2 in area
were not included in our results. We also investigated the frequency distribution of the
number of cells with specific nuclear sizes or staining intensities (Fig 11). Median and
average nuclear sizes were not significantly reduced by the first hit, supporting the view
that the cells surviving the first hit are indeed viable (Fig 9). However, average nuclear
size was slightly decreased after two MG132 insults, suggesting cells were stressed and
perhaps undergoing apoptosis. Therefore, we performed the TUNEL assay for apoptotic
cells but discovered that the first MG132 hit did not change the number of TUNELpositive cells. The second MG132 hit significantly increased the number of TUNELpositive cells in both the control and previously stressed groups, but the total numbers of
apoptotic cells were low (~10%), suggesting that the vast majority of cells counted after
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dual hits are indeed viable. It is also important to note here that we were excluding the
small, dying cells in our viability assays. These findings are entirely consistent with our
observations that astrocytes survived dual hits even when the interval between the first
and second hits was increased to 96h and when the interval between the second hit and
the time of assay was increased to 72h. Had the cells been progressing towards cell death,
we would not expect to have continued to see protection in the latter studies.
An examination of the scatterplots of nuclear size versus staining intensity
suggests that the first hit eliminated cells with small nuclear sizes (50-150 µm2) and
bright staining intensities (greater than 20 arbitrary units for mean gray value). Indeed,
cells with small nuclei were more likely to die and wash off the plate at the time of assay
than cells with larger nuclei, as shown in Figure 11. Small, bright cells may be in the
process of dying and the MG132 treatment may force them beyond the threshold needed
to survive. These findings of preferential loss of the smaller cells continue to support the
hypothesis that MG132 treatment kills the most vulnerable cells and leaves behind the
more resistant survivors.
Based on a large body of work, astrocytes are no longer considered a relatively
uniform population of cells (Hewett, 2009; Y. Zhang & Barres, 2010). In addition to
regional differences in the properties of astrocytes, astrocytes within a given brain region
are also structurally and functionally diverse. As argued by Hewett, astrocyte adaptability
or plasticity contributes to this diversity (cite the man again!!). Early studies had already
established that astrocytes can be divided into protoplasmic and fibrous groups, which are
found in gray and white matter, respectively, and exhibit unique morphological
characteristics (R. H. Miller & Raff, 1984). Astrocyte heterogeneity has been
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hypothesized to contribute to the differential vulnerability of specific brain regions to
neurodegenerative disorders. For example, astrocytic glutathione levels are higher in the
cerebral cortex relative to the substantia nigra in Parkinson’s disease and may explain the
relative resistance of the former brain region to pathology in this condition. Even within
the cortex itself, astrocytes exhibit heterogeneity, as they do not uniformly express the
GFAP and S100β markers (Emsley & Macklis, 2006). This heterogeneity may also be
reflected in the differential expression of S100β and GFAP in our cortical astrocyte
cultures; that is, a small number of cells in our cultures only expressed one of these two
markers. Further evidence of astrocyte heterogeneity in our model is the fundamental
observation that some astrocytes succumbed to the first hit of MG132 whereas others
survived this insult and were resistant to further injury. As mentioned above, we observed
higher vulnerability of astrocytes with small, brightly stained nuclei relative to astrocytes
with large nuclei. An important goal for future studies would be to determine the unique
protein profiles of these two distinct groups. One might speculate that the cells with
larger nuclei have undergone some degree of hypertrophy in vitro, a classic anatomical
sign of cellular stress, and that they are more likely to engage the enzymes responsible for
glutathione synthesis and redox cycling, such as glutamate cysteine ligase, glutathione
reductase, and glutathione peroxidase. Alternatively, cortical astrocytes may naturally
include both large and small cells and these in vivo features may be retained under in
vitro culturing conditions. It is worth noting that the astrocytes that survived MG132
exhibited marked changes in their qualitative appearance, shifting from a stellate shape to
a bipolar, fusiform, or rounded shape, and expressing higher levels of GFAP (Figure 2).
Consistent with the view that astrocyte heterogeneity influences their ability to develop
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stress tolerance, there are reports of differential vulnerabilities of cortical astrocyte
subpopulations after diffuse traumatic brain injury (Hill, Barbarese, & McIntosh, 1996).
Previous work suggests that preconditioned astrocytes can still support neuronal
functions (Sen, et al., 2011). However, it is not clear whether severely stressed astrocyte
survivors promote or prevent neuronal injury. Some authors have hypothesized the
reverse, namely that injured astrocytes exacerbate neuronal injury (Fogal, Li, Lobner,
McCullough, & Hewett, 2007; Gouix, et al., 2014; Jana & Pahan, 2010; Pertusa, GarciaMatas, Rodriguez-Farre, Sanfeliu, & Cristofol, 2007). Thus, we sought to determine
whether stressed astrocyte survivors can protect neurons from proteotoxicity. As
expected, we observed that severely stressed astrocytes can still protect neighboring
neurons from proteotoxic injury. Although glutathione was essential for astrocytic stress
resistance, astrocytes did not rely on glutathione defenses in order to protect neurons
from proteotoxicity. This finding was unexpected because previous work has shown that
astrocytes protect neurons by releasing glutathione precursors into the extracellular space
(Dringen, et al., 2000; Dringen, et al., 1999). Hsp70 is also known to be released from
astrocytes via exosomes and may decrease proteotoxicity in other models through this
transcellular process (Taylor, et al., 2007). However, neither inhibition of Hsp70 by
VER155008 nor glutathione by buthionine sulfoximine attenuated astrocyte-mediated
neuroprotection in our hands. It is possible that VER155008 may not be as effective in
the mixed cultures as it is in the neuron-only group simply because there are more cells
present. However, the stressed astrocyte group with lower cell numbers was more
protective than the unstressed astrocyte group with higher cell numbers, suggesting that
greater uptake of inhibitors at lower cell densities did not confound our interpretations.
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The astrocyte-mediated neuroprotection in our model appeared to be dependent
upon cell-cell contacts and not a diffusible factor (Fig 20). For example, the
neuroprotective effects may occur through the diffusion of a small molecule via gap
junctions (Kozoriz et al., 2010; Nakase, Sohl, Theis, Willecke, & Naus, 2004).
Alternatively, astrocytes may protect neurons by the uptake of excess glutamate from the
extracellular space, which would require them to be present at the time of neuronal
excitotoxicity (Romera et al., 2007). Astrocyte-conditioned medium was concentrated by
ultra-centrifugation concentrating devices in a preliminary study but showed the same
results as unconcentrated medium. One possible explanation of these findings is that
glutathione may diffuse through the concentrating device owing to its small size. If this
were the case, it would not be delivered to the neurons in the conditioned media exchange
experiments and we would fail to observe neuroprotection. Alternatively, astrocytes may
release the diffusible factor immediately following the proteotoxic insult and this factor
may be degraded in the 24h interval between the MG132 insult and conditioned media
exchange.
As mentioned earlier, GFAP is a highly stress-responsive cytoskeletal protein
thought to be primarily expressed by astrocytes (Eng, Ghirnikar, & Lee, 2000). Changes
in GFAP expression levels have been attributed to astrocytosis and/or astrocyte
hypertrophy(Eng, et al., 2000). Mutations in GFAP have been reported in Alexander’s
disease (Tang, Perng, Wilk, Quinlan, & Goldman, 2010). In this condition, GFAP+
protein aggregates may be associated with a toxic gain of astrocyte function (Brenner et
al., 2001; Messing, Brenner, Feany, Nedergaard, & Goldman, 2012). However,
attenuation of astrocyte reactivity can also be detrimental to neurological recovery after
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injury (Liu et al., 2014) and astrocyte cytoskeletal proteins and cellular reactivity are
thought to be essential for maintaining the astrocyte neurosupportive functions. For
example, recent studies demonstrate that loss of GFAP increases neuronal loss in the
brain (Schreiner et al., 2015). Although forced overexpression of GFAP is associated
with early death in mice (Messing et al., 1998), many studies suggest that physiological
GFAP upregulation serves to preserve homeostasis. For example, GFAP is essential for
mitigating traumatic brain injury (Nawashiro, Messing, Azzam, & Brenner, 1998).
Furthermore, motor neurons in the spinal cord become dysfunctional in the absence of
GFAP (Schreiner, et al., 2015). All of these studies are consistent with the findings of the
present study that reactive astrocytes can continue to support neurons, even under
conditions of severe injury and after synergistic loss proteasome and Hsp70 chaperone
functions.
In conclusion, our studies suggest that astrocytes can adapt to severe
proteotoxicity, a form of plasticity that may have evolved so that this cell type retains its
capacity to support neuronal functions. Thus, neurons surrounded by reactive astrocytes
may be able to survive for longer periods under conditions of proteotoxic stress. It may
be difficult to generate severely stressed astrocytes in an in vivo model because the
elimination of even small numbers of astrocytes might incapacitate some neuronal
functions (Wagner et al., 2006). For example, compromises in astrocytic function may
contribute to neurodegeneration in Alexander’s disease (Brenner, et al., 2001; Messing, et
al., 2012). A more targeted approach to eliciting severe proteotoxicity in astrocytes alone
and one that does not elicit astrocyte death seems warranted.
Study limitations
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A number of limitations, in addition to the ones alluded to above, must be
conceded. First, all pharmacological inhibitors exert nonspecific effects at high
concentrations. As a result of this concern, we used concentrations that are established in
the literature, but this does not preclude some off-target effects. One approach to
blocking heat shock protein activity more specifically in the future might be to use RNA
interference. However, this method would not circumvent potential compensatory
responses of other proteins. For example, other heat shock protein family members may
be upregulated in response to loss of Hsp70 function. It is also important to note that
MG132 inhibits proteases such as cathepsin A, cathepsin B, and calpain 1 in addition to
its inhibition of the proteasome, as mentioned in the Introduction (Rivett & Gardner,
2000). However, the inhibition of these proteases would still contribute to proteotoxic
effects. For this reason, our model is described as one of loss of protein homeostasis,
defined as proteotoxicity, rather than selective proteasome inhibition (Morimoto, 2008).
Second, one might argue that the astrocytes surviving MG132 do not mount any
active defenses against proteotoxicity but are simply inherently less susceptible to this
toxin from the very beginning. If the stressed cells were always inherently less
susceptible, one would expect these cells to have elevated defensive molecules at all
times relative to untreated cells. If this were indeed the case, one would not expect to
observe the transient upregulation of Hsp70, HO1, and ubiquitinated proteins after the
first hit as we did. Furthermore, stressed astrocytes exhibited robust increases in Hsp70,
HO1, and ubiquitinated proteins after the second hit whether or not they had previously
been stressed, suggesting that we had not selected for a population of cells that were
refractory to the effect of the toxin. Finally, if astrocytes had not mounted any defenses in
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response to MG132, then inhibition of the stress-induced increase in glutathione would
not have rendered them vulnerable to the toxic effects of dual MG132 hits. In effect,
glutathione loss unmasks the toxic impact of the second hit. All these data support the
view that the astrocytes mount active defenses in response to proteotoxicity.
In our studies, astrocytes were able to attenuate proteotoxicity in neurons despite
being exposed to high concentrations of MG132 prior to the introduction of neurons (Fig
18A and 19A). These findings are the first to demonstrate that severely stressed
astrocytes surviving a lethal insult can still protect neighboring neurons from proteotoxic
injury although there are greatly reduced in numbers. It is possible that the effects of
MG132 in the neuron-astrocyte coculture group may be attenuated simply because there
are greater numbers of cells present to take up the MG132 than the neuron-only cultures.
However, as mentioned above, this hypothesis is not consistent with the observation that
astrocytes previously exposed to MG132 (and therefore reduced in numbers) are even
more protective than the unstressed astrocytes (with greater numbers) in the experiments
delivering MG132 and VER155008 simultaneously or MG132 and BSO simultaneously
(Fig 19 and 18).
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4.2 N-acetyl cysteine protects against protein-misfolding stress in an Hsp70dependent manner
NAC has been shown to exert some beneficial effects in patients with psychiatric
and neurodegenerative diseases, perhaps by reducing oxidative stress (Adair, et al., 2001;
Berk, Copolov, Dean, Lu, Jeavons, Schapkaitz, Anderson-Hunt, Judd, et al., 2008; Berk,
Copolov, Dean, Lu, Jeavons, Schapkaitz, Anderson-Hunt, & Bush, 2008; M. E. Hoffer, et
al., 2013). In experimental Parkinson’s disease, NAC has been shown to decrease αsynuclein+ aggregates, an established sign of protein-misfolding stress, perhaps by raising
glutathione defenses (Clark et al., 2010). Various doses and delivery methods have been
used to administer NAC in the clinic. Soldiers experiencing blast injuries were
administered 4 grams of NAC daily for 4 days after injury followed by 3 grams daily for
the remainder of the study (M. E. Hoffer, et al., 2013). Rather strikingly, this regimen
doubled the chances of resolution of neurological symptoms from 42% to 86%. A similar
oral dose of NAC was given to Alzheimer’s disease patients in capsule form (50
mg/kg/day) (Adair, et al., 2001). NAC was shown to increase brain glutathione levels in
Parkinson’s disease patients when delivered at 150 mg/kg by intravenous infusion for one
hour (Holmay, et al., 2013). However, NAC is thought to have an oral bioavailability of
only 9.1% (Olsson, Johansson, Gabrielsson, & Bolme, 1988). On the other hand, many
studies have shown that orally delivered NAC can have protective effects on neurons in
vivo and increase brain glutathione levels in experimental models of neurological
disorders, suggesting it crosses the blood-brain barrier in sufficient quantities (Grant,
Odlaug, & Kim, 2009; R. W. Hurd, Wilder, Helveston, & Uthman, 1996; Lavoie et al.,
2008). Nevertheless, chemical modifications to NAC have been investigated due to
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perceived poor bioavailability (Giustarini, Milzani, Dalle-Donne, Tsikas, & Rossi, 2012;
Sunitha et al., 2013). Either way, the effective in vitro concentration (3 mM) used in the
present investigation likely surpasses concentrations delivered to cells in in vivo studies.
It is possible that higher concentrations are needed in vitro than in vivo because of high
basal levels of oxidative stress under in vitro culturing conditions (Halliwell, 2014).
Further studies are warranted to continue to improve NAC bioavailability.
NAC has already been shown to decrease cellular stress in astrocytes in
experimental models of ischemia and pain (Bernabucci et al., 2012; Gabryel, Toborek, &
Malecki, 2005). As mentioned previously, astrocytes exhibit protein-misfolding stress in
neurodegenerative diseases (Allen & Barres, 2009; Braak, et al., 2007; Kimelberg &
Nedergaard, 2010). Because astrocytes help preserve neuronal function, it is important to
identify therapies that protect astrocytes from protein-misfolding stress in order to
mitigate loss of neuroprotective features. Our study demonstrates that NAC might be one
such candidate. Other studies in the Leak lab have shown that NAC can also protect
cortical neurons and neuroblastoma cells against proteotoxic and oxidative stress,
supporting the view that the protective effects of NAC are generalizable across multiple
experimental models (Posimo, et al., 2013; Unnithan, et al., 2012; Unnithan et al., 2014).
The generalizability across different models improves the chances of success in the
clinic.
As mentioned above, previous studies in the Leak lab have shown that NAC
protects neuroblastoma cells against MG132 (Jiang, et al., 2013). In those studies,
MG132 was effective at inhibiting the chymotrypsin-like activity of the proteasome in the
presence or absence of NAC. Furthermore, in our astrocyte study, expression of
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proteasomal subunits was not altered by NAC treatment. In contrast, the dramatic
MG132-mediated rise in ubiquitin-conjugated proteins was abolished by NAC in both
neuroblastoma cells and astrocytes. Taken together, these findings suggest that NAC
decreases proteotoxicity through a mechanism independent of direct effects on
proteasome activity. Had NAC directly reduced the effects of MG132 on the proteasome,
we would not have been able to conclude that it protects against protein misfolding stress
because the toxin would simply be less effective in the NAC-treated group. Instead, NAC
may be reducing the burden of misfolded, ubiquitinated proteins by improving chaperone
and antioxidant defenses (see below).
Neurodegenerative diseases are characterized by both protein-misfolding and
oxidative stress, which propel and propagate each other and amplify the injury. For
example, proteasome inhibition has been shown to increase oxidative stress (Maharjan, et
al., 2014). NAC is thought to provide the rate-limiting component in glutathione
synthesis (E. Hoffer, et al., 1996). However, in our astrocytes, NAC was protective
independent of glutathione synthesis, as its therapeutic potential was not abolished by
buthionine sulfoximine. Unexpectedly, NAC attenuated the MG132-mediated rise in
glutathione. However, NAC has been observed to attenuate stress-induced rises in
glutathione in other models, demonstrating that our findings are not entirely
unprecedented (Tchantchou, Graves, Rogers, Ortiz, & Shea, 2005). Although NAC
attenuated proteotoxicity independent of glutathione synthesis, NAC may nevertheless
reduce oxidative stress in astrocytes by the direct antioxidant activity of the thiol group
(Aruoma, et al., 1989). This may prevent oxidative damage to proteins, including Hsp70
and other chaperones, and as a result, decrease proteotoxicity. Furthermore, if NAC
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directly reduces oxidative stress, this may explain the mitigation of the stress-induced rise
in glutathione levels.
The cysteine of NAC can exist in two isomeric forms: L-cysteine and D-cysteine.
Both forms of the amino acid can reduce oxidative stress through redox cycling of the
cysteine sulfhydryl group. L-cysteine but not D-cysteine can be incorporated into
glutathione. In our studies, both L-cysteine and D-cysteine were shown to protect
astrocytes against MG132 toxicity, as was observed with NAC. Some amino acids can be
converted from the D- to L-isoform by D-amino acid oxidase (Friedman & Levin, 2012;
Sacchi, et al., 2008). Thus, D-cysteine may decrease proteotoxic stress by first being
converted to L-cysteine followed by incorporation into glutathione. However, inhibition
of D-amino acid oxidase with sodium benzoate did not alter the protective effect of Dcysteine in our study (Katane, et al., 2013; Van den Berghe-Snorek & Stankovich, 1985),
suggesting that the conversion reaction was not significant in our model. Future studies
are needed to confirm that L-cysteine is directly protective and not protective through
interconversion to glutathione, perhaps by using buthionine sulfoximine to inhibit
cysteine incorporation into glutathione. Nevertheless, all the data collected thus far in our
model are consistent with the view that protection by NAC is not dependent upon
glutathione synthesis. Thus, we speculate that the robust protection by NAC may depend
upon the cysteine sulfhydryl group, which is also present in both L-cysteine and Dcysteine.
Thiol exchange reactions can facilitate activation of transcription factors such as
Nrf2 and HSF1 (Dinkova-Kostova, 2012). For example, NAC might be expected to react
with cysteine residues on Keap1. As a result, Keap1-mediated degradation of Nrf2 would
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be attenuated, enabling its translocation from the cytoplasm to the nucleus and the
transcription of genes such as HO1 and HSPA1B, which encodes Hsp70 (Hu, et al., 2006;
Kwak, et al., 2003; Qi et al., 2013). Similarly, thiol exchange reactions between NAC and
the cysteine residues in HSF1 might elicit transcription of Hsp70 genes. However, our
studies showed that NAC attenuated MG132-mediated increases in HO1 and Hsp70
expression. Contrary to the results observed in astrocytes, other studies in our lab have
shown that NAC increases Hsp70 in N2a cells (Jiang, et al., 2013) and in cortical neurons
(unpublished findings). The reasons underlying this discrepancy are still under
investigation.
Although NAC attenuated the MG132-mediated rises in Hsp70 and HO1, we
investigated whether inhibition of Hsp70 and HO1 activity attenuated NAC-mediated
protection because changes in protein levels do not always coincide with changes in
activity. Three pharmacological inhibitors for Hsp70 (VER155008, pifithrin-μ, and
MAL3-101) with different mechanisms of action and one pharmacological inhibitor of
HO1 (SnPPx) activity all attenuated astrocytic protection by NAC. These findings
suggest that Hsp70 and/or HO1 activity is important for NAC-mediated protection. It
remains possible that NAC preserves Hsp70 or HO1 activity under conditions of
oxidative stress by direct antioxidant action. For example, NAC may prevent oxidative
damage to these proteins. Other studies in the Leak lab have also shown that Hsp70
inhibitors abolish NAC-mediated protection in N2a cells, cortical neurons, and
hippocampal neurons, suggesting that NAC protects multiple cell types in an Hsp70dependent manner.
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Heat shock proteins such as Hsp70 and HO1 are known to be higher in patients
with neurodegenerative diseases relative to control subjects, probably because the stimuli
to induce their expression include proteotoxic and oxidative stress (Schipper, et al., 2006;
Schipper, et al., 1998; Wu et al., 2004). The upregulation of these heat shock protein
molecules may be a compensatory response to damage to some fraction of the heat shock
protein pool, resulting in a loss of negative feedback on heat shock protein gene
transcription and translation. NAC may protect in part by reducing further damage to heat
shock proteins and in turn, this may enable more efficient refolding and degradation by
Hsp70 and superior heme degradation by HO1. Based on the dramatic reduction in
ubiquitinated proteins and the potential facilitation of Hsp70 refolding activity, NAC is
expected to slow or halt further accumulation of protein aggregates in patients with
neurodegenerative conditions.
As described above, measurements of Hsp70 activity are not feasible in cellular
lysates because many molecules in these lysates exhibit ATPase activity in addition to
Hsp70. It is therefore not possible to assess whether NAC protects astrocytes by
increasing Hsp70 activity in the astrocyte model. To address this gap, one might assess
the activity of pure, recombinant Hsp70 in the presence of NAC (Z. Lu & Cyr, 1998),
although such experiments would not establish a definitive mechanism in the astrocyte
model. Cysteine residues on Hsp70 are susceptible to oxidative damage that might hinder
ATPase activity (Miyata, et al., 2012). If NAC reverses damage to Hsp70, this would
suggest that NAC decreases proteotoxicity by preserving normal Hsp70 function.
As mentioned above, all pharmacological inhibitors have off-target effects at high
concentrations. Therefore, multiple pharmacological inhibitors were used to examine the

122

role of Hsp70 activity in NAC-mediated protection against MG132. VER155008 and
pifithrin-µ are known to inhibit autophagy, but this may occur through inhibition of
Hsc70 (Budina-Kolomets et al., 2013; Leu, et al., 2011), because Hsc70 escorts proteins
to the lysosome for autophagic degradation (Arias & Cuervo, 2011). Despite potentially
nonspecific effects, the overlapping effects of the inhibitors suggest that Hsp70 activity
loss is indeed responsible for reducing NAC-mediated protection. In other words, it
would be unlikely that all three inhibitors have the same non-specific effects.
In conclusion, protein aggregate buildup may be attenuated by NAC through the
thiol-mediated prevention of disulfide bond formation (Samuni, Goldstein, Dean, & Berk,
2013). The accumulation of protein aggregates may also be reversed in the presence of
Hsp70 (Chittoor-Vinod, Lee, Judge, & Notterpek, 2015). Our studies reveal that NACmediated protection of astrocytes is dependent upon Hsp70 activity. Preservation of
astrocyte function by NAC would be expected to contribute to neuronal homeostasis and
slow down the neurodegenerative process.
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4.3 Natural aging elicits changes in heat shock proteins in multiple brain regions
Heat shock proteins are important for restoring protein homeostasis under
conditions of proteotoxic stress. Perez and colleagues found that longevity is determined
in part by protein stability and resistance to oxidative damage (Perez et al., 2009). Some
studies have shown that heat shock protein defenses wane with advancing age while
others have shown age-related increases in heat shock proteins (Alladi, et al., 2010;
Dickey, et al., 2009; Ewing & Maines, 2006; Gupte, et al., 2010; C. K. Lee, Weindruch,
& Prolla, 2000; Paz Gavilan, et al., 2006). The impact of aging in the substantia nigra and
striatum on heat shock proteins has been previously examined (V. Calabrese, et al., 2004;
Ewing & Maines, 2006; Gupte, et al., 2010; Unno, et al., 2000). However, all of these
animal studies were conducted in males. Thus, the present study is the first to assess the
relationship between natural aging and heat shock protein expression in the substantia
nigra, striatum, and olfactory bulb in female rats.
In this study, some heat shock proteins, such as Hsp25 and Hsp70, were observed
to increase with advancing age. These increases may be the result of compensatory
responses to age-related proteotoxic and oxidative stress. For example, cells may elevate
heat shock protein levels to reverse or slow the detrimental effects of age-related loss of
proteasome activity (Martinez-Vicente, et al., 2005). As misfolded proteins are
ubiquinated prior to proteasomal degradation, proteotoxic stress was measured by
assessing ubiquitin-conjugated proteins in our studies. The statistical trends towards agerelated increases in pan ubiquitin-conjugated proteins in the substantia nigra and striatum
are suggestive of an increase in proteotoxic stress. Furthermore, K48-linked ubiquitin in
the striatum was higher in older animals in comparison to 4-6 month old rats. However,
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no significant increases in K48-linked ubiquitin levels were observed in the substantia
nigra. K48-linked ubiquitin is a more direct assessment of proteotoxicity than pan
ubiquitin as some molecules are ubiquitinated without being targeted to the proteasome.
For example, linkages between ubiquitin molecules at lysine 63 signal endocytosis,
kinase activation, and DNA damage, and not proteasomal degradation (Sadowski &
Sarcevic, 2010). Measuring proteasome activity would be an important goal for future
aging studies in our model.
The female Sprague Dawley rat has been shown to have a lifespan ranging from
193-1100 days (Davis, Stevenson, & Busch, 1956). The oldest animals in our study were
sacrificed at 22 months because some began to exhibit poor health and die. Even older
animals might have exhibited a more robust increase in proteotoxic stress. In future
studies we would need to house a large number of animals to account for high rates of
spontaneous death after two years of age.
A thorough understanding of age-related disruptions to proteostasis and the
response of heat shock proteins to these changes is important for the identification of new
therapeutic targets. However, some authors have argued that aging animal models have
poor predictive validity. Sengupta and colleagues reviewed factors such as teeth, sexual
development, and musculoskeletal systems as important for relating rat age to human age
(Sengupta, 2013). Based upon these factors, the authors suggested that rats encounter
developmental stages at different rates than humans and therefore, caution must be
exerted when correlating rat to human ages. In other words, changes in heat shock protein
expression at specific rat ages may be difficult to extrapolate to human developmental
stages.
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Depending upon the brain region examined, some heat shock protein defenses,
such as Hsp40 and Hsc70 were observed to wane with advancing age. These effects
would be expected to contribute to a progressive accumulation of protein aggregates.
Despite declines in expression of these heat shock proteins, age-related increases in
ubiquitinated proteins were small in size, suggesting that other heat shock proteins may
have compensated for deficits in these proteins. Thus, the overall severity of age-related
proteotoxicity is likely to be the result of the concerted efforts of multiple heat shock
protein defenses and proteasomal and autophagic clearance mechanisms.
In our work, we have shown that the relationships between aging and heat shock
proteins are highly dependent upon brain region. For example, Hsp25 increased in the
female rat olfactory bulb, striatum, and substantia nigra with aging. For example, Hsp25
was higher in 4-22 month animals in comparison to the youngest animals in the olfactory
bulb. This may be suggestive of developmental changes in Hsp25 expression. As both the
striatum and the nigra exhibited a rise in Hsp25, we hypothesized that Hsp25 may be
present within the dopaminergic neurons that form the nigrostriatal pathway. Confocal
analyses confirmed that Hsp25 was present in tyrosine hydroxylase+ dopaminergic
neurons of the substantia nigra. In addition, Hsp25 was also present in cells not
expressing tyrosine hydroxylase, as one might expect given the ubiquitous nature of this
heat shock protein. If the number of dopaminergic neurons decrease with aging as has
been reported in some models, the rise in Hsp25 observed in the present study may be
attributed to Hsp25 expression within other cell types (Gibb & Lees, 1991).
As mentioned above, the confocal analysis suggests that Hsp25 is expressed in
both dopaminergic and non-dopaminergic cells in the ventral mesencephalon. Some of
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the Hsp25-expressing non-dopaminergic cells are expected to be glial in nature, as Hsp25
is known to be highly expressed in astrocytes (Chen & Swanson, 2003; Stetler, Gao,
Signore, Cao, & Chen, 2009). Hsp25 expression has been shown to be increased in
various models of neurological disorders and with natural aging (Crum et al., 2015a;
Gleixner, et al., 2014; Gupte, et al., 2010; Strey et al., 2004). For example, Hsp25
expression within glial cells is increased in transgenic models of amyotrophic lateral
sclerosis (Wang, Martin, Gonzales, Borchelt, & Lee, 2008). Future studies to investigate
the differential impact of aging and proteotoxicity on Hsp25 levels in glial and neurons
are warranted, as they may provide insight into the differential susceptibility of various
cell types to proteotoxicity.
Several authors have speculated that the olfactory bulb is especially vulnerable to
protein inclusions in neurological disorders because of greater exposure to environmental
pathogens than deeper brain regions. For example, α-synuclein+ aggregates appear in the
olfactory bulb long before they emerge in the ventral mesencephalon in Parkinson’s
disease (Hawkes, Del Tredici, & Braak, 2009). Based on these histological observations,
one would expect to see heat shock protein changes in the olfactory bulb before similar
changes appear within the nigrostriatal pathway in Parkinson’s patients. Future studies to
test this hypothesis might help correlate the emergence of Lewy pathology with stress
responses in heat shock proteins. Such findings would also be consistent with histological
studies showing that Lewy bodies contain high levels of Hsp70 molecules (Shin,
Klucken, Patterson, Hyman, & McLean, 2005).
Some heat shock protein responses to aging differed between the substantia nigra
and striatum. For example, HO1 was decreased with aging in the substantia nigra,
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whereas a biphasic response in HO1 levels was observed in the striatum. The discrepancy
between the nigral and striatal HO1 changes may suggest that HO1 is present in cells
other than dopaminergic neurons of the nigrostriatal pathway. Despite our repeated
efforts to address this question, multiple antibodies against HO1 were ineffective by
immunohistochemistry and only worked in Western blot analyses.
An age-related decline in Hsc70 was observed in both the olfactory bulb and the
striatum. As mentioned above, Hsc70 recognizes proteins with the KFERQ-like sequence
and escorts them to the lysosome for chaperone-mediated autophagic degradation (Boya,
Reggiori, & Codogno, 2013). A loss of Hsc70 expression with aging would therefore be
expected to contribute to autophagic stress. As expression of the membrane protein
LAMP2A is thought to reflect levels of chaperone mediated autophagy (Boya, et al.,
2013), future studies to measure LAMP2A protein levels to assess age-related changes in
autophagy in the olfactory bulb and striatum might be valuable.
For our in vivo studies, we used female rats. Advancing age leads to cessation of
estrous cycling in female rats (Sone et al., 2007). It is possible that fluctuations in the
estrous cycle may have contributed to some of the high variability observed in some of
the heat proteins. Estrous cycling is already known to have an impact on Hsp25
expression (Steffl, Telgen, Schweiger, & Amselgruber, 2010). Similarly, Hsp70
expression levels also fluctuate with the estrous cycle (Muthukumar et al., 2014). In
order to reduce variability, vaginal smears to determine the phase of the estrous cycle
might be helpful. However, if the data were stratified according to the estrous cycle, we
would need many more animals in each group.

128

In conclusion, aging is the most important risk factor for the development of
neurodegenerative diseases, all of which are characterized by loss of proteostasis and
changes in heat shock proteins (Alladi, et al., 2010; Dickey, et al., 2009; Ewing &
Maines, 2006; Gupte, et al., 2010; Keller, Hanni, & Markesbery, 2000b; Keller, Huang,
et al., 2000; C. K. Lee, et al., 2000; Martinez-Vicente, et al., 2005; Paz Gavilan, et al.,
2006; Van Den Eeden, et al., 2003). However, not all aged individuals suffer from
neurodegenerative diseases and it is therefore important to understand heat shock protein
defenses in the absence of pathological changes. It is worth noting that our study of the
relationship between normal aging and heat shock proteins was only correlative and did
not establish any causal links. In order to assess the importance of the observed changes
in heat shock proteins, knockout, knockdown, or antagonism experiments would be
necessary. Alternatively, the proteins in question might be overexpressed to determine if
this increases lifespan and protects against insults in experimental models. The
information garnered in the present study would be useful in guiding such future
investigations.
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